Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

Haixia Wang1,2†, Yi He1,2†, Zuoli Sun1,2, Siyu Ren1,2, Mingxia Liu1,2, Gang Wang1,2* and Jian Yang1,2*

Abstract
Major depressive disorder is a highly debilitating psychiatric disorder involving the dysfunction of different cell types in the brain. Microglia are the predominant resident immune cells in the brain and exhibit a critical role in depression. Recent studies have suggested that depression can be regarded as a microglial disease. Microglia regulate inflammation, synaptic plasticity, and the formation of neural networks, all of which affect depression. In this review, we highlighted the role of microglia in the pathology of depression. First, we described microglial activation in animal models and clinically depressed patients. Second, we emphasized the possible mechanisms by which microglia recognize depression-associated stress and regulate conditions. Third, we described how antidepressants (clinical medicines and natural products) affect microglial activation. Thus, this review aimed to objectively analyze the role of microglia in depression and focus on potential antidepressants. These data suggested that regulation of microglial actions might be a novel therapeutic strategy to counteract the adverse effects of devastating mental disorders.

Keywords: Major depressive disorder, Microglial activation, Antidepressants, NLRP3 inflammasome, Neurogenesis, Kynurenine pathway

Background
Major depressive disorder (MDD) is a public health problem that affects approximately 322 million people worldwide [1]. During the coronavirus disease 2019 (COVID-19) pandemic, a meta-analysis reported that 45% of COVID-19 patients experienced depression [2]. Over 700,000 people die from suicide every year due to depressive disorder, which results in a heavy burden on individuals and society [3]. Clinical symptoms of MDD include persistent low mood, appetite loss, decreased interest in favorite activities, despair, sleepy disorders, and, in severe cases, suicidal behavior [4]. Unfortunately, due to its complexity and heterogeneity that are determined by genetic and environmental factors, the biological mechanisms underlying depression remain unclear. Currently, theories concerning depression primarily focus on the monoamine neurotransmitter depletion hypothesis, neuroplasticity hypothesis, and hypothalamus–pituitary–adrenal (HPA) axis hypothesis [5]. However, limitations are associated with these specific pathological mechanisms, such as an inability to explain the delayed effect of antidepressants and a lack of focus on cells other than neurons in the central nervous system (CNS) [6, 7].

Microglia are the first line in the innate immune system in the CNS and actively regulate microenvironmental changes in healthy and disordered brains. Microglial activation regulates inflammation, synaptic...
refinement, synaptic pruning, and neuronal connectivity [8]. Depression is considered a microglia-associated disorder (microgliopathy) [9]. Ample evidence suggests that microglia-mediated neuroinflammation interacts with all three theories correlated with MDD listed above [10, 11]. Neuroinflammation and the HPA axis are thought to function in a coordinated manner, and their dysregulation might mediate the onset of depression [10, 12–14]. Some clinical antidepressants affect the activation of microglia and neuroinflammation [15–17]. Nonsteroidal anti-inflammatory drugs appear to alleviate depressive symptoms by inhibiting microglial activation [18]. Minocycline is a semisynthetic tetracycline antibiotic that decidedly improves depressive-like behaviors by inhibiting microglial activation in the prefrontal cortex (PFC) and hippocampus (HIP) [19]. Microglial activation can be divided into the classic activation of M1 or alternate activation of M2 under optimal conditions [20]. Recently, pharmacological principles that modulate microglial polarization may provide beneficial treatments to alleviate the recurrence of psychiatric disorders [21–23].

Therefore, we conducted a systematic review using the Pubmed electronic database. Search themes included depression and microglia, neurogenesis, stress, and antidepressants. Articles from 1992 to 2021 were reviewed that focused on the connection between microglia and depression. In this review, we described the activation states of microglia in animal models and clinically depressed patients. We elucidated the mechanisms underlying depression and the therapeutic potential of targeting microglia. Finally, we highlighted the protective effects of antidepressants that act through modulating microglia in stress-induced animal models of depression.

**Microglia: origin and function**

**Origin and development of microglia**

Microglia were first described as a distinct cell type by Spanish neuroscientist Pio del Rio-Hortega in 1919 and account for approximately 5–10% of the total cell population in the brain [24]. The number of microglia in the adult mouse brain is estimated at 3.5 million, with variations in density across different regions. For example, more microglia are found in the HIP, substantia nigra (SN), olfactory telencephalon, and basal ganglia. Fewer microglia are observed in the fiber tracts, cerebellum, and the majority of brainstem [25]. Ontogenetically, recent fate-mapping studies have revealed that microglia originate from erythromyeloid progenitor cells in the developing embryonic yolk sac, and migrate into the embryonic CNS to differentiate into mature microglia. CNS microglia form a self-renewing cell population through proliferation and apoptosis throughout life of the individual [26, 27].

**Characteristics and functions of microglia**

As CNS immune effector cells, microglia are similar to peripheral macrophages with respect to their morphology and functions [28]. Under normal conditions, neurons serve a regulatory role in the CNS. Microglia provide protection and nutritional support to neurons, influence neuronal homeostasis, regulate synaptogenesis, and activate astrocytes (Fig. 1) [29, 30]. Resting microglia are characterized by a small soma with multiple symmetrically distributed protrusions that protrude at a rate of 0.4–3.8 μm/min to maintain either an extended or contracted state to sense changes in surrounding environment. Microglia are maintained in a relatively resting state in part by signals from neurons and astrocytes [31]. In response to challenges, such as tissue injury, pathogens, or other pathological processes, microglia quickly respond to the homeostatic imbalance and undergo considerable morphological transformation to provide defense mechanisms [32]. Specifically, the processes retract, the soma enlarges, and the ramifications of the distal branches decrease. Activated microglia undergo additional morphological change and present a characteristic “amoeba-like” shape. The number of transformed microglia increases, and they migrate to the injured site at a rate of 1–2 μm/min for tissue repair [33, 34]. The activated microglia gradually shift from providing nutritional support and repairing neurons to neuronal dysfunction. These changes in function may be more persistent after continuous exposure to certain stimuli. This response further recruits peripheral innate immune cells (e.g., macrophages) and adaptive immune cells (e.g., B cells) to cross the blood–brain barrier and eventually lead to cognitive and emotional disorders [35–37].

**The polarization of microglia**

Microglia exist in a resting state under normal physiological conditions and carry out “immune surveillance” functions [38, 39]. When CNS damage or infection occurs, microglia can be broadly divided into the classic activation (M1) or alternative activation (M2) phenotype. M1 microglia result in pro-inflammatory cytokine release and increased expression of several differentiation marker 86 and 16/32 (CD86, CD16/32) and inducible nitric oxide synthase (iNOS). M2 microglia are inclined to express anti-inflammatory cytokines, arginase-1 (Arg1), transforming growth factor-β1 (TGF-β1), CD206, and chitinase-3-like-3 [22]. M1 microglia remove apoptotic cells, pathogens, and inhibit normal neuron growth, which adversely affects synaptic transmission.
M2 microglia promote phagocytosis of cell fragments and misfolded proteins, tissue repair, and support neuron survival. Intriguingly, M2 microglia are driven by the coordinated regulation of multiple anti-inflammatory mediators and against M1-induced inflammation that ultimately achieve immune suppression and neuronal protection (Fig. 2) [40].

However, the status of microglia may include a range of different but overlapping functional phenotypes that are in response to changes in their local environment. Novel single-cell technologies, such as single-cell RNA sequencing and cytometry by time-of-flight mass spectrometry, have emerged as superior methods to characterize immune cell types and states, the transition from normal to disease, and respond to therapy. For instance, microglia were isolated from LPS-injected mice that showed downregulation of homeostatic markers (e.g., Tmem119, Mef2c, P2ry13, P2ry12, and Siglech) and upregulation of inflammatory genes (e.g., Ccl2, Gpr84, and Nfkbia) by single-cell RNA sequencing and multicolor flow cytometry [41]. In the brains of a transgenic mouse model of Alzheimer’s disease (AD), a novel type of microglia (disease-associated microglia, DAM) was identified using single-cell analysis. Researchers further discovered that Trem2 is necessary for transformation from DAM stage-1 to DAM stage-2 [42]. With the development of unbiased and high-throughput analytical methods, it is possible to comprehensively characterize the spatial and temporal heterogeneity of microglia during CNS development and disease [43, 44]. Based on current research of microglial phenotypes, the classification using M1 and M2 subtypes is oversimplified and not universally accepted. We will use “pro-inflammatory” or “anti-inflammatory” microglia in subsequent descriptions to highlight the contribution of microglia in depression.

Microglia in depression

Clinical evidence

A growing body of research has shown that damage to the typical structure and function of microglia in the developing and adult brain is associated with the etiology of depressive disorders. Changes in microglia in different brain regions, including the PFC, HIP, anterior cingulate cortex (ACC), and amygdala, are involved in the development of depression. Previous studies have shown that considerable microglial activation occurs in the PFC and
ACC during severe episodes of MDD. Microglial activation in ACC also is positively correlated with the severity of the depressive episode [45]. Positron emission tomography (PET) scans have shown that microglia are increased in ACC during episodes of MDD [46]. At the same time, the TSPO levels (a marker of microglial activation) were increased in MDD patients [47]. A cross-sectional study using 18F-FEPPA PET showed a strong relationship between the total distribution volume of TSPO and the duration of untreated MDD, total illness duration, and antidepressant exposure [48]. Correspondingly, in an autopsy study of patients with MDD, the concentrations of quinolinic acid (QUIN) produced by microglia were increased in the subgenual ACC and anterior midcingulate cortex of suicide victims [49]. In the dorsal ACC white matter from depressed suicide patients, microglial density was increased significantly, as identified by elevated gene expressions of ionized calcium-binding adapter molecule 1 (Iba-1), CD45, and monocyte chemoattractant protein-1 [50]. Another study reported similar results that were obtained in the prefrontal white matter [51]. Nevertheless, the role of microglia-mediated inflammation in the occurrence of depression is still controversial. Additional evidence demonstrated that microglia decrease in depression. In subjects with familial MDD, glia cells were clearly reduced while the number of neurons remained unchanged [52]. Brain imaging revealed cortical atrophy in the subgenual part of Brodmann's area 24 [52]. A similar reduction in glial density was also observed in the orbital cortex, ACC, and dorsolateral PFC, based on a laminar analysis [53–55]. In addition, the numbers of glial cells were reduced, especially on the left side of the amygdala in MDD patients, when assessed using stereological methods [56]. However, no reduction in the numbers of glia was found in area 3b of the somatosensory cortex in patients with depression, suggesting that glial reduction in mood disorders is limited to specific brain structures [57].

In addition to depression disorder, microglial activation has been reported in other mental disorders such as anxiety [58], schizophrenia [59], and autism spectrum disorders [60, 61]. Anxiety disorders often emerge early in life and are associated with other diseases. Clinical reports on microglia and anxiety disorders remains extremely limited, except in animal models of depression [58]. A PET imaging study demonstrated increased microglial activity in patients with schizophrenia and persons at ultra-high risk of psychosis [62]. In autism, increases in microglia were observed in cortical areas (fronto-insular and visual cortex) of the brain [63]. Conversely, several studies reported no significant microgliosis or changes in the expression of glial cell markers in schizophrenia and autism [60]. Therefore, there are different opinions concerning microglial activation in the development of...
these mental diseases, which may be related to assessments during different stages of disease onset or individual heterogeneity. The treatment of depression should be personalized based on the status of major depression and microglial function in individual patients. It also is worth noting that suicide has a high prevalence in the long-term course of mental diseases. Postmortem analysis has revealed that an elevated microglial density in schizophrenia and depressive patients is associated with suicide [59], indicating altered microglial activity might be critical in psychiatric disorders.

Preclinical evidence
Considerable research has focused on the relationship between MDD and microglia in various animal models. Sustained microglial activation that exhibited high levels of pro-inflammatory cytokines has been observed in different brain regions [64–68], while inhibition of microglia alleviated depressive-type behaviors [69]. In this review, we illustrated the effects of microglial activation in animal models of depression, including acute/chronic stress and rodent pharmacological models. The search themes that were used included “LPS, chronic mild stress (CMS), chronic social defeat stress (CSDS), chronic restraint stress (CRS), olfactory bulbectomy (OBX), or learned helplessness (LH) combined with microglia and depression, respectively. The results indicated that microglia involved in nearly all models mentioned above. Among them, microglia were most evident in the models associated with LPS, CMS, and CRS, as well as CSDS-induced neuroinflammation, as shown in Fig. 3.

In a mouse model of acute depression, intraperitoneal injection of LPS activated the nod-like receptor pyrin containing 3 (NLRP3) expression and IL-1β cleavage in the HIP. Immunofluorescence staining showed that NLRP3 was primarily expressed in Iba-1 positive microglia when compared with control mice [70]. In BV2 microglial cells, LPS exposure induced an imbalance between the pro-inflammatory and anti-inflammatory microglial phenotype [71], activated TLR4/nuclear factor-kappa B (NF-κB) pathway, and downregulated TREM2 expression [72]. In the HIP and cortex of CMS-exposed mice, immunofluorescence staining revealed that the activated microglia (Iba-1 positive cells), as well as increased pro-inflammatory microglial markers (IL-1β, TNF-α, IL-6, INF-γ, and iNOS) and decreased
anti-inflammatory markers (Ym1, IL-4, IL-10, and Arg-1), suggesting a transformation of the microglial phenotype [73]. The CSDS paradigm also produces mood alterations and microglial activation, as well as ROS elevation. In addition, depletion of microglia using PLX5622 protects against behavioral abnormalities in the light–dark (LD) and social interaction (SI) tests [74]. These studies provide evidence that depressive-like behaviors and inflammation are present in chronic stress and pharmacological rodent models, which might be associated with persistent interference in microglia-related signaling. Other animal models that demonstrate an association between depression and microglia are shown in the Additional file 1: Table S1.

Since 1992, numerous studies have verified the concept that CNS microglia-mediated inflammation may contribute to depression and is closely related to regional selectivity and disease severity. Even though a strong correlation between microglia and depression has been observed in patients and animal models, determining whether microglial abnormalities actually play a significant role in depression remains challenging.

**The role of microglia in the pathogenesis of depression**

*Microglia–neuron communication in depression*

Microglia–neuron communication functions bi-directionally. Microglia impart considerable influence on numerous aspects of neuronal function. Similarly, neurons regulate microglial functions mainly through soluble factors such as chemokines, cytokines, and neurotransmitters. Among these factors, CX3CL1 and CD200 are primarily expressed by neurons, and their receptors, CX3CR1 and CD200R, are expressed on microglia [75]. Dysfunctional interactions between neurons and microglia are critical factors in severe neurological disorders, including depression, schizophrenia, and AD.

The communication between CX3CL1 and CX3CR1 contributes to the ability of microglia to maintain functional stability. Depending on the degree of brain damage, CX3CL1 leads to increased microglia pro-inflammation or maintenance of microglia in a quiescence state [76, 77]. In a LPS-induced depression model, the decreased expression of CX3CL1 and microglial activation were observed in the HIP [78]. The serum levels of CX3CL1 in patients with moderate–severe depression were higher than in the control group [79]. A similar observation was made for the plasma levels of CX3CL1 from MDD patients with co-morbid cocaine addiction [80]. Cx3cr1-deficient mice displayed transient microglial reductions during the early postnatal period and subsequent defects in synaptic pruning. Defective synaptic pruning has been associated with less effective synaptic transmission and decreased neural circuit formation, and social interaction, as well as increased repetitive behavior, which also have been observed in several neuropsychiatric disorders. These findings suggest that microglia-mediated disruption of synaptic pruning could be associated with neurodevelopmental and neuropsychiatric disorders [81]. More importantly, previous studies have suggested that hyper-ramified microglia (process branching and/or soma enlargement) is connected to depressive-like behavior in rodents. The CX3CR1-deficient mice showed definite resistance to repetitive swim stress-induced depressive-like behavior and microglia hyper-ramification changes compared to wild-type mice [82]. Also, CX3CR1-deficient mice also demonstrated the impairment in long-term potentiation (LTP). Treatment with an IL-1β receptor antagonist significantly reversed the cognitive function and synaptic plasticity impairments observed in CX3CR1-deficient mice [83]. The prenatal stress produced behavioral disturbances in anxiety and depressive behavior in adult offspring of rats. The underlying mechanism may be related to the upregulation of CXCL12 and its receptor, as well as decreased CXCL1-CX3CR1 expression in the HIP and frontal cortices, whereas exogenous CXCL1 application alleviated the observed changes [84, 85]. Furthermore, CX3CR1 deficiency has been shown to impair neuron–microglia responsiveness to chronic stress [86]. Treatment with antidepressants such as fluoxetine, venlafaxine, or tianeptine normalized these behavioral and biochemical alterations [84].

Recently, CD200-CD200R has been shown to be related to the pathogenesis of depression through animal models studies that focused on using different stress-inducing protocols. For instance, exposure to inescapable tail shock resulted in reduced CD200R level in the HIP, basolateral (BLA), and central nucleus of the amygdale [87]. Similar observations have been reported in male and female rats [88]. However, a paradoxical observation indicated that unavoidable foot shocks in rats reduced the transcription level of CD200R in the hypothalamus, but not the HIP [89]. These discrepancies between published reports concerning the HIP might be attributed to the use of different protocols by the two research groups. In an IFN-α-induced model of depression, vulnerable mice displayed increased levels of MHC-II, CD86, and CD200R. These mice displayed depressive-like behaviors characterized by increased immobility time in the forced swimming test (FST) and tail suspension test (TST), as well as decreased explorative behavior in the novel object exploration test [90].

**Microglia and neurogenesis in depression**

During brain development, microglia regulate synaptic transmission, prune neuronal synapses, and facilitate
the formation of neural circuits. Once homeostasis is disturbed, microglia are converted into an active state and release pro-inflammatory cytokines, chemokines, and reactive oxidants. The pro-inflammatory microglia are involved with the upregulation of pro-inflammatory mediators, which is usually considered a harmful event. Whereas anti-inflammatory microglia display protective effects in neuronal survival and adult neurogenesis [91].

Activation of microglia is a critical mechanism in neurogenesis inhibition in the presence of inflammation and stress [9]. Hippocampal neurogenesis is a complex neurobiological process involving the generation and functional integration of newborn cells into brain neural circuits [92]. Several studies have demonstrated that stress strongly suppresses adult hippocampal neurogenesis. Both acute and chronic stress have been reported to reduce adult neurogenesis by decreasing neuroprogenitor proliferation and newborn cell survival [93–95], and also impair newborn neuron maturation [96, 97]. LPS infusion via a cannula for 4 weeks reduced the survival of new neurons in the subgranular zone/granule cell layer (SGZ/GCL) of the HIP, while 6 days of intracortical LPS infusion in rats did not affect the proliferation of new cells [98]. In addition, LPS-induced neuroinflammation suppressed proliferation and differentiation of neural stem cells in the dentate gyrus (DG) of the HIP, which was indicated by the decreased number of BrdU-, DCX- and NeuN-positive cells [99]. In an 8-week CMS-induced depression paradigm, C57BL/6 mice exhibited an increase in the number of Iba-1 positive cells and levels of IL-1β, IL-6, and TNF-α [100]. Another report on the CMS showed that an imbalance of peripheral inflammation markers and decreased CX3CL1/CX3CR1 immunoreactivity were associated with reduced numbers of BrdU/Ki-67/DCX+ (nascent, proliferating and DCX-associated) cells in the DG of the HIP [101]. Furthermore, in a graded study of the CMS for 5, 6, or 7 weeks, the investigators found that the pro- or anti-inflammatory microglial changes in the cortex and HIP, as well as BrdU/DCX+ cells, decreased in the DG [102]. Similar results related to the relationship between depressive-like behaviors and changes in microglia and neurogenesis have been reported in psychosocial stress models, including maternal separation [103], maternal sleep deprivation [104], chronic water-immersion restraint stress (CWIRS) [105], and CSDS [106, 107]. On the other hand, IL-4 and IL-10 induce alternative activation of anti-inflammatory factors that play a critical neuroprotective function in tissue remodeling and nerve regeneration. Treatment with IL-4 markedly inhibited IL-1β-caused depressive behavior by regulating glial activation and neurotransmitter levels in the HIP [108]. IL-4 stimulation increased the expression of insulin-like growth factor-1 in microglia, which has been reported to promote neurogenesis [109, 110]. Recent research demonstrated that IL-4-driven Arg1+ microglia modulate stress resilience through brain-derived neurotrophic factor (BDNF)-dependent neurogenesis in CMS mice [111]. IL-10-stimulated microglia enhanced the proliferation of NPCs but did not affect neuronal differentiation. IL-10-secreting microglia supported neuronal differentiation and the survival of newly formed cells in vitro [112]. CX3CR1CreERIL-10 knockout mice exhibited depression- and anxiety-like behaviors, along with decreased NR2B (N-methyl-D-aspartate receptor (NMDAR) subunit) and synaptophysin (SYP) levels in the mPFC, and increased NR2B and postsynaptic densin-95 (PSD95) levels in the amygdala [113]. Furthermore, hippocampal neurogenesis was reduced in CX3CR1-deficient mice, and antagonizing CX3CR1 resulted in increased hippocampal IL-1β level and decreased neurogenesis in young rats [114]. Minocycline, a microglial inhibitor, reversed the pathogenic phagocytotic potential of neurotoxic microglia, and reduced the negative phenotypes associated with reduced neurogenesis in depression models induced by chronic stress and LPS [115]. Therefore, these data suggest that microglia are correlated with reduced neurogenesis induced by exposure to stress and, in turn, may be responsible for the development of depressive-like behaviors.

**Microglia-mediated activation of NLRP3 in depression**

The NLRP3 inflammasome is a multi-molecule complex containing cytosolic NLRP3, adaptor protein ASC, and pro-caspase-1 precursor. NLRP3 plays a vital role in production of pro-inflammatory cytokines during the stress process [116]. The NLRP3 inflammasome is currently considered to be an essential molecular platform for regulating pro-inflammatory cytokines release. NF-κB nuclear translocation is an indispensable event in the initiation of NLRP3 activation, which further confirmed that NF-κB nuclear translocation might play a role in assembling the NLRP3 inflammasome. When NLRP3 is activated by repetitive stress, it modulates caspase-1 activation, which, in turn, promotes IL-1β and IL-18 maturation in microglia, where excessive secretion of cytokines contributes to the development and progression of MDD [117–119].

NLRP3 inflammasome activation has even been observed in depressive patients and numerous animal models of depression. Previous studies have revealed that the NLRP3 inflammasome was activated in blood cells from MDD patients, and the levels of IL-1β and IL-18 were increased in serum. The increase in pro-inflammatory factors was positively correlated with Beck Depression Inventory scores [120], suggesting that NLRP3...
might have a critical role in mediating the development of depression [121]. In another experimental study, a sustained CMS procedure (12 weeks) enhanced the levels of IL-1, NLRP3, ASC, TLR2, NF-κB, p-IKKα, and IKKβ in rat PFC, while these alterations were reversed with fluoxetine [122]. Immunofluorescent analysis has confirmed that the NLRP3 inflammasome was primarily activated only in microglia in the PFC (Iba-1/NeuN+ cells) [122]. Using NLRP3 inflammasome inhibitors AC-YVAD-CMK and VX-765 significantly improved depressive-like behavior, as shown by improvements in sucrose intake in the sucrose preference test (SPT) and immobility time in the FST of CMS mice [94, 123]. Moreover, activation of the sucrose preference test (SPT) and immobility time in CMK and VX-765 significantly improved depressive-like symptoms [133]. KP metabolizes tryptophan into kynurenine metabolites leads to subsequent depressive-like symptoms [133]. KP metabolizes tryptophan into kynurenine metabolites leads to subsequent depressive-like symptoms [133]. In a LPS-induced acute depression mouse model, NLRP3, ASC, and caspase-1 mRNA expressions were remarkably increased compared to the control group [125]. In addition, IL-1β secretion was densely controlled by the NLRP3 inflammasome, which plays an important role in the pathogenesis of depression [108]. Minocycline has an acute antidepressant role in CRS, CUMS, and LH models by inhibiting microglia and NLRP3 activation [126–129]. Fluoxetine conferred an antidepressant effect in part by inhibiting NLRP3 inflammasome activation [130]. Clomipramine reversed LPS-induced increases in IL-1β, IL-6, TNF-α, and NLRP3 gene expressions in vivo, as well as in vitro in BV2 cells [131]. Electro-acupuncture treatment for 4 weeks markedly reversed CMS-induced increases in NLRP3 inflammasome-associated components (NLRP3, ASC, and caspase-1) and the expressions of mature IL-1β, as well as IL-18, TNF-α, IL-6, P2X7 receptor, and Iba-1 [132]. Iptakalim negatively regulates NLRP3 expression and, in turn, affects microglia-mediated neuroinflammation by inhibiting the activation of NLRP3/caspase-1 axis in the HIP of CMS mice [94]. These findings suggest that microglial NLRP3 activation is a central mediator involved in depressive-like behaviors in animal models and MDD patients.

**Microglia-mediated kynurenine pathway in depression**

Chronic stress stimulation or inflammation may contribute to tryptophan (TRP) metabolism associated with the kynurenine pathway (KP). The generation of neuroactive kynurenine metabolites leads to subsequent depressive-like symptoms [133]. KP metabolizes tryptophan into several bioactive metabolites in the brain, including QUIN (an NMDAR agonist) and kynurenic acid (KYN, an α7-AChR and NMDAR antagonist). KYN is primarily formed in astrocytes [134], which exhibit a neuroprotective function via their ability to eliminate glutamate spillover. QUIN is produced mainly by microglia [135] and has a strong excitotoxic role through enhancing NMDAR activation [136]. Microglia regulate KP balance by preferentially producing oxidative metabolites, including QUIN. Other metabolites of KP, including 3-hydroxykynurenine (3-HK) and anthranilic acid, do not directly affect neuronal activity but are involved in complicated pro-oxidation and anti-oxidation processes [137].

Recent studies have found that microglial QUIN expression was increased in the subgenual and supracallosal regions of the ACC in post-mortem brains of suicide patients with severe depression. In contrast, additional research revealed decreased QUIN in left CA1 or right CA2/3 areas of the HIP in unipolar depression patients [138]. Moreover, a meta-analysis revealed decreased KYNA and kynurenine (KYN) levels in patients with depression and increased QUIN level in antidepressant-free patients [139]. Similar results have been reported concerning the increase of QUIN in peripartum depression and adolescent MDD [140, 141]. In addition to clinical data, enhanced levels of 3-HK and QUIN have been observed in several models of depression [142, 143]. LPS and other infectious agents, including viruses, upregulate the release of inflammatory cytokines by binding to TLRs, which in turn directly and indirectly induce KP metabolism via pro-inflammatory cytokines [144]. Ketamine treatment could reduce the LPS-induced depressive-like alterations observed in the novelty suppressed feeding test (NSFT) and splash test (ST) [145]. In a genetic animal model, the level of KYNA was reduced in the PFC of Flinders sensitive line rats compared with Flinders resistant line control rats [146]. In addition, CMS contributed to QUIN production and its release from microglia in the HIP. QUIN resulted in the elevation of Glu level via NMDARs and mGluR1, as well as the increased expression of NR2B and mGluR1, which lead to depressive-like symptoms [147]. CRS exposure induced depressive-like behavior in C57BL/6 J mice, which was attributed partially to disruption of the neuroprotective/neurotoxic balance of the kynurenine metabolic pathway in the gut and brain [148]. Enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is considered to be a rate-limiting enzyme for tryptophan metabolism in KP [149]. Treatment with the IDO inhibitor, 1-methyltryptophan, partially prevented CRS-induced depression- and anxiety-like changes [148]. The chronic forced swim test and tail suspension test in mice enhanced KYN/TRP and reduced the 5-HT/TRP ratio, which indicated activation of IDO1 [150]. In the poststroke depression (PSD) mouse model, 3-hydroxyanthranilate 3,4-dioxygenase (HAOO), QUIN, IDO1, Iba-1, and ROS were remarkably increased in the nucleus accumbens (NAc), HIP, and hypothalamus. At the same time, treatment
with aripiprazole ameliorated the abnormal behaviors in PSD mice that were accompanied by decreased levels of IDO1, HAAO, QUIN, and ROS [151]. IDOInh is a specific inhibitor of IDO1 and has been shown to reverse fear learning and memory in CSDS-induced depressed mice by decreasing KYN and 3-HK levels in the blood and brain [152]. Consequently, it has been proposed that kynurenine metabolites directly interact with microglial activity, which provides a reliable target for investigating the mechanisms underlying antidepressant drugs.

**Effects of antidepressants on microglia**

Currently, numerous reports using different experimental models have indicated that antidepressants, including clinical and plant-based drugs, exert their antidepressant effects, in part, by regulating microglial phenotypes. Regulation of microglia has been proposed as a potentially effective therapeutic strategy in chronic inflammatory diseases [29, 30]. In this section, we summarized the current knowledge of antidepressants (clinical medicine and natural products) that act against microglial dysfunction in stress-induced depression models (Tables 1 and 2).

**Clinical antidepressive drugs**

Clinical antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), have exhibited effects on microglial activation and neuroinflammation [153]. Other compounds, including minocycline, melatonin, FCPR16, pioglitazone, iptakalim, and caffeine, also influence microglial polarization and depressive-like behavior [91], as shown in Table 1.

The SSRIs (fluoxetine, citalopram, and escitalopram) exhibit antidepressant roles in LPS, CMS, CSDS, and CWIRS models, as seen by alleviating nest-building deficits, reducing immobility time in the FST and TST, and increasing sucrose intake in the SPT (Table 1). These behavioral changes were accompanied by decreases in the microglial marker Iba1 expression in different brain regions. In addition, pro-inflammatory factors levels (IL-1β, TNF-α, and NO) were downregulated, and anti-inflammatory factors levels (IL-4, IL-10, Arg-1, and TGF-β1) were upregulated [16, 101, 105, 154, 155]. Tricyclics, including clomipramine and imipramine, reversed depressive behaviors induced by LPS, LH, and CSDS by reducing the number of activated hippocampal microglia (Table 1). These traditional antidepressants promote the activation of anti-inflammatory microglia to release anti-inflammatory cytokines and neurotrophic factors, suggesting that reducing inflammation may be part of the function of clinical antidepressants [107, 131, 156]. Cytokines levels are strongly correlated with the efficacy of antidepressant treatment in patients. For example, higher levels of IL-6 and TNF-α are more commonly found in treatment-resistant patients than responders [157]. Nevertheless, some results revealed conflicting views that antidepressants might sometimes increase the inflammatory load in the brain. For instance, citalopram treatment elevated the levels of TNF-α and IFN-γ in the PFC, and these effects were inhibited by the anti-inflammatory agent ibuprofen [158]. Phenelzine, a monoamine oxidase inhibitor, has been shown to enhance the microglia-mediated immune responses by increasing the expressions of iNOS, TNF-α, and IL-6 in LPS-treated BV-2 cells. It has been verified that phenelzine also increased the levels of NO, TNF-α, and IL-6 via the NF-κB signaling pathway in LPS-activated primary microglia cells [159]. These differences may depend on regional brain specificity and heterogeneity among depression models and patients, but the conflicting causes and mechanisms need further study. Ketamine has exhibited potential antidepressant effects in vivo and in vitro by inhibiting microglia-mediated neuroinflammation [160]. Partial depletion of microglia with PLX3397 blocked the rapid and sustained antidepressant effects of (R)-ketamine (an isomer of ketamine), suggesting that antidepressant effects of ketamine may be partly attributed to microglial activation [161].

Minocycline is a potential agent for the treatment of depression [19]. In several studies, chronic minocycline treatment clearly alleviated depressive-like symptoms by inhibiting microglia and HPA axis hyperactivity. The powerful neuroprotective effects of minocycline were mainly mediated by modulating pro-inflammation and anti-inflammation balance in the PFC and HIP, as well as upregulating the BDNF-mediated synaptic plasticity in stress models [14, 162–164]. Meanwhile, CMS-induced changes in behavior, hippocampal LTP, CD11b expression, NLRP3 inflammasome, BDNF, and p-GluR1 levels were restored with chronic minocycline treatment [128, 165–168]. Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that regulates inflammation and microglial polarization and is a potential treatment target in MDD. Pioglitazone, a PPARγ agonist, significantly ameliorated depressive-like behaviors in CMS mice by regulating the expression of pro-inflammatory markers (IL-1β, IL-6, TNF-α, iNOS, and CCL2) together with anti-inflammatory markers (Ym1, Arg1, IL-4, IL-10, and TGF-β) in the HIP [169]. Other drugs that play a potential antidepressant role in modulating microglial phenotype are shown in Table 1.

**Plant-derived natural compounds and formulations with antidepressant properties**

Recently, the regulatory properties of some plant-derived natural compounds and formulations have shown efficacy in treating depression. In this review, the antidepressive
| Treatment       | Animal models     | Behavioral test | Analyzed regions | Microglians          | Pro-inflammation | Anti-inflammation |
|-----------------|-------------------|-----------------|------------------|----------------------|------------------|-------------------|
| Fluoxetine [154]| CSDS              | OFT, EPM, SIT   | Serum            | lba-1(–)            | ELISA: TNF-α ↓, HMBG1 ↑ | mRNAs: TNF-α, IL-1β, RAGE, TLR4 ↑ | Pro-             |
|                 |                   |                 |                  | Iba-1(-)            |                  |                   | inflammation     |
| Fluoxetine [170]| CMS               | Nest-building test, Dexamethasone suppression test | Cortical Amygdala HIP | CD11 b/P2X7R↑, CD11 b/P2X7R↓ | —                  | —                 | Anti              |
| Fluoxetine [105]| CWIRS             | SPT, FST, TST   | HIP              | Proteins: CD68, lba-1 ↓ | ELISA: IL-1β, TNF-α, iNOS ↓ | —                 | —                 |
| Fluoxetine [155]| LPS               | SPT, FST        | HIP              | lba-1/COX-2↑↓ in DG | ELISA: IL-1β, IL-6, TNF-α | Pro-             |
| Citalopram [101]| CMS               | SPT, FST        | HIP              | lba-1*↑↑↑↑, CX3CL1↑↑↑↑ CX3CR1↑↑↑↑ in DG | —                  | —                 | Anti              |
| Escitalopram [16]| CMS               | OFT, SPT, TST, FST, NSFT | Hip Cerebral cortex | —                  | —                  | —                 |
| Imipramine [107]| CSDS              | SIT, SPT, TST, FST | Serum HIP | —                  | —                  | —                 |
| Sertraline [171]| CMS               | SPT, TST, FST   | PFC              | lba-1/HMBG1↑↓ | ELISA: TNF-α, IL-1β ↓ | —                 |
| Sertraline [172]| CMS               | TST, FST        | Brain            | Protein: lba-1 ↓  | ELISA: TNF-α, IL-1β, IL-6 ↑ | —                 |
| Vortioxetine [17]| LPS               | OFT, SPT, NORT  | Dorsal HIP       | mRNA: CD14, CD86 ↑ | mRNA: TNF-α, IL-6, IDO1 ↑ | mRNA: IL-4, TGF-β1 ↑ |
| Imipramine [173]| Repeated social defeat | OFT, social avoidance test | Plasma Brain | mRNA: CD14, CD11b ↑ | mRNA: IL-1β, IL-6, TGF-β, Arg-1 ↓ | —                 |
| Imipramine [156]| LH                | —               | Hilus            | lba-1*↓↑ | —                  | —                 |
| Clomipramine [131]| LPS              | TST, FST        | HIP              | lba-1*↓↑ | —                  | —                 |
| Agomelatine [174]| LPS               | —               | vHIP             | mRNA: CD11b, CX3CL1, CX3CR1 ↓, CD58 ↑ | —                  | —                 |
| Melation [70]   | LPS               | TST, FST        | HIP              | lba-1/IL-1β, IL-6 ↑ | —                  | —                 |
| SRT2104 [175]   | CMS               | OFT, SPT, TST, FST | HIP | lba-1*, CD11b*↑CD45*↑ | mRNA: IL-6, IL-1β, iNOS ↓ | mRNA: IL-10, TGF-β, Arg-1 ↑ CD11b*↑CD206*↑ |
| Pioglitazone [169]| CMS              | OFT, SPT, TST, FST | HIP | lba-1*↓ | mRNA: IL-1β, TNF-α, Arg1, IL-4, CD206*↑ |

**Table 1: Traditional antidepressants regulate the microglia-mediated neuroinflammation in animal models of depression**
The effect of natural products such as ginsenosides (Rg1, Rg3, and Rb1), resveratrol, salvianolic acid B, and magnolol on microglia-mediated neuroinflammation are summarized in Table 2. The chemical structures of several natural compounds that may act as potential inhibitors of pro-inflammatory microglial activation in MDD are illustrated in Fig. 5.

### Table 1 (continued)

| Treatment          | Animal models | Behavioral test | Analyzed regions | Microglia | Pro-inflammation | Anti-inflammation |
|--------------------|---------------|-----------------|------------------|-----------|------------------|------------------|
| Clemastine [176]   | CMS           | SPT, TST, FST   | Serum            | HIP       | ELISA: IL-1β, TNF-α ↓ | —                |
|                    |               |                 |                  | Protein: Iba-1 ↓ |                  | Protein: Arg-1 ↑  |
| Minocycline [163]  | OBX + spinal nerve ligation | OFT | PFC              | —         | mRNA: IL-1β, IL-6 ↑ | mRNA: MRC2, IL-10 ↑ |
| Minocycline [14]   | CMS           | SPT, FST, EMP   | Serum            | HIP       | mRNA: CD11b, IFN-γ/IL-4, IFN-γ/IL-10 ↓ | —                |
|                    |               |                 |                  | mRNAs: CORT ↓ |                  | mRNA: TGF-β1, IL-4, IL-10, IL-13 ↑ |
| Memantine [177]    | OBX           | Emotional behavior, TST, FST | HIP | Iba-1 ↑ | Proteins: p-IkBα, p-p65, NF-kB, TNF-α, IL-6 ↓ | —                |
| Iptakalim (94)     | CMS           | SPT, TST, FST   | Serum            | HIP       | ELISA: IL-1β ↓ | mRNA: TNF-α, IL-6 ↓ |
|                    |               |                 |                  | MAC-1 ↑, in DG | mRNA: TNF-α, IL-6 ↓ | mRNA: IL-10 ↑ |
| Simvastatin [178]  | LPS or CMS    | SPT, FST, NSFT  | HIP              | Iba-1 ↑ | Proteins: p65, IL-1β, NLRP3, caspase-1 ↓ | —                |
| ONO-2952 [179]     | CSDS          | OFT, EMP, TST, FST | NAc | — | Proteins: TNF-α, IL-6 ↓ | —                |
|                    |               |                 |                  | BLA       | Proteins: TNF-α, IL-6, IL-12 ↓ | —                |
|                    |               |                 |                  | PFC       | Proteins: IL-1β, IL-12 ↑ | —                |
|                    |               |                 |                  | vHip      | Protein: IL-12 ↓ | mRNA: TNF-α, TLR4, IL-β ↓ | —                |
| Iptakalim [180]    | CRS           | OFT, FST        | Hypothalamus     | TNF-α/CD11b ↓ | mRNA: TNF-α, IL-10 ↑ | —                |
| Caffeine [105]     | CWIRS         | SPT, FST, TST   | HIP              | Protein: Iba-1 ↓, CD68+ ↓ | Protein: CD68, iNOS, TNF-α, IL-1β ↓ | —                |
| Apelin-13 [181]    | CWIRS         | OFT, SPT, TST, FST | HIP | Iba-1 ↑, Iba-1/ iNOS↑, Iba-1/ Arg-1↑ in CA1 | Proteins: IL-1β, IL-6, IL-12 ↓ | —                |
| Melatonin [101]    | CMS           | SPT, FST        | HIP              | Iba-1↑, CX3CL1↑, CX3CR1↑↑ in DG | — | —                |
| ω-3 polyunsaturated fatty acids [182] | Ovariectomized | SPT, FST, NSFT, TST | HIP | Iba-1↑ in DG | mRNA: IL-1β, IL-6, TNF-α, CD68 ↓ | mRNA: IL-4, IL-10, CD206, Arg-1 ↑ |
|                    |               |                 |                  | mRNAs: p-p65, IkB, iNOS ↓ | mRNA: CD11b ↑ | Protein: Arg-1 ↑ |
| Fingolimod [183]   | CMS           | OFT, SPT, FST, WMW | HIP | mRNA: Iba-1 ↑ | ELISA: IL-1β, IL-6, TNF-α ↓, mRNAs: NLRP3, ACS, caspase-1, iNOS, CD16 ↓ | ELISA: IL-10 ↑, mRNA: Arg-1, CD206 ↑, Proteins: Arg-1, CD206 ↑ |

↑ upregulated; ↓ downregulated; (–) no significant difference; — no explicit data

### Flavonoids

Flavonoids are subgroups of flavonoids composed of a backbone of 2-phenylchrcromen-4-ketone, and their biological activities have been reported in vitro and in vivo [184]. Flavonoids achieve their antidepressive effects through modulating microglial activation and NLRP3 inflammasomes. Baicalin, a flavonoid found in the root of Scutellaria, could ameliorate depressive behaviors in
Table 2  Plant-derived natural compounds and formulations that regulate microglia-mediated neuroinflammation in animal models of depression

| Treatment | Animal models | Behavioral test | Analyzed regions | Microglia | Pro-inflammatory | Anti-inflammatory |
|-----------|---------------|-----------------|------------------|-----------|-----------------|------------------|
| Crocin [226] | LPS | OFT, FST, TST, FST | HIP | — | ELISA: IL-1β, IL-18, TNF-α ↓ | Protein: CD206 ↑ |
| Baicalin [186] | CMS | OFT, FST, TST, FST | HIP | — | Proteins: IL-1β, IL-6, TNF-α, TLR4 ↓ | — |
| Catalpol [205] | CMS | OFT, EPM, FST | HIP | Iba-1↑↓ | mRNA: IL-1β, TNF-α, iNOS, IL-6, CD68 ↓ | Protein: CD206 ↑ |
| Ganoderic acid A [227] | MCAO + CMS | OFT, SPT | HIP | — | ELISA: TNF-α, IL-1β, IL-6 ↓ | ELISA: IL-10 ↑ mRNA: IL-10, CD206, Arg-1 ↑ Proteins: CD206, Arg-1 ↑ |
| Ginsenoside Rb1 [73] | CMS | OFT, SPT, TST, FST | HIP | Iba-1↑↓ | mRNA: TNF-α, IL-1β ↓ | — |
| Salvianolic acid B [213] | CMS | SPT, TST, FST | HIP | Iba-1↑(−) | ELISA: TNF-α ↓ mRNA: IL-1β, TNF-α ↓ | ELISA: IL-10 ↑ mRNA: IL-10, TGF-β ↑ |
| Curcumin [215] | GWI + CRS | OLT, NORT, NSFT | HIP | Iba-1↑↓ | — | — |
| Arctigenin [171] | CRS | OFT, TST, FST | HIP | — Protein: Iba-1 ↓ | — |
| Astragalin [231] | CMS | SPT, TST, FST | HIP | Iba-1↑↓ | mRNA: TNF-α, IL-1β ↓ | — |
| Saikosaponin-d [190] | LPS | OFT, FST, TST, FST | HIP | Iba-1↑↓ in CA1 | Proteins: CD68, IL-1β, IL-6, TNF-α, HMGB1, TLR4, p65-NF-kB, p-IκB-α ↓ | — |
| Asperosaponin VI [228] | LPS | OFT, FST | HIP | Iba-1↑↓ | mRNA: IL-1β, IL-6, TNF-α, iNOS ↓ Proteins: IL-1β, TNF-α, TLR4, p-NF-kB/ NF-kB ↓ PFC mRNA: IL-1β, IL-6, TNF-α, iNOS ↓ Proteins: IL-1β, TNF-α, TLR4, p-NF-kB/ NF-kB ↓ | — |
| 5-O-Methylvisammoside [233] | LPS | OFT, FST, EPM | HIP | — | Proteins: NF-kB, IκB-α ↓ | — |
| Treatment | Animal models | Behavioral test | Analyzed regions | Microglia | Pro-inflammatory | Anti-inflammatory |
|-----------|---------------|----------------|-----------------|-----------|----------------|-----------------|
| Scutellarin [230] | LPS | OFT, SPT, FST | HIP | Iba-1↓ | Proteins: NLRP3, caspase-1, IL-1β↓, ROS↓ | — |
| Ginsenoside Rg1 [200] | CMS | SPT, FST | vmPFC | Iba-1↓ | mRNA: IL-1β, IFN-γ, TNF-α↓, ELISA: IL-1β, IFN-γ, TNF-α↓ | — |
| Ginsenoside Rg3 [201] | LPS | — | Cortex, Hypothalamus, Brain | iNOS+, COX-2+, Iba-1↓ | mRNA: IL-1β, IL-6, TNF-α | — |
| Magnolol [219] | CMS | OFT, SPT, FST, TST | HIP | Iba-1↓ in DG; Iba-1/Cd16/32↓, Iba-1/Cd206↑ | — | ELISA: TNF-α, IL-1β, IL-6, IL-12↓, mRNA: Arg1, Ym1, Fizz1, Klf4↑ |
| Geniposide [208] | LPS | SPT, TST, FST, OFT | HIP | — | ELISA: TNF-α, IL-6↓ | mRNA: CD86, CD206↑ |
| Arctin [210] | CMS | TST, FST, OFT, SPT | PFC | Iba-1↓, HMGB1↑ | Proteins: TNF-α, IL-1β, iNOS, HMGB1↑ | — |
| Ginkgolide B [234] | Depression in post myocardial infarction | OFT, SPT | MEDIAN RAPHE NUCLEUS | — | ELISA: IL-1β↓ | mRNA: IL-1β↓ |
| Leonurine [235] | CMS | TST, FST, SPT | HIP | — | Proteins: IL-1β, IL-6, TNF-α, p-IKKβ/iKKβ, p-p65/p65↓ | — |
| Hesperidin [232] | CMS | FST, SPT, OFT | PFC | Iba-1↓ | mRNA: NLRP3, caspase-1, ASC↓, Proteins: NLRP3, caspase-1, ASC↓, ELISA: IL-1β, IL-6, TNF-α↓ | — |
| 20(S)-Protopanaxadiol [229] | CMS | SPT, TST, FST | HIP | Iba-1↓ | Proteins: iNOS, COX-2, acetylated p65 (ac-p65)↓ | — |
| Ferulic acid [236] | CMS | SPT, FST | PFC | — | mRNA: IL-6, IL-1β, TNF-α, NF-kB, CD11b↓, Proteins: NLRP3, caspase-1↓ | — |
| Resveratrol [224] | LPS | OFT, TST, FST | HIP | Iba-1↓ in DG-SGZ | — | — |
| (+)-Sesamin [69] | CMS | OFT, FST, TST, EMP | HIP | Protein: Iba-1↓ | mRNA: COX-2, iNOS, IL-1β, TNF-α↓ | — |
| Quercetin [187] | OBX | OFT, FST | HIP | — | ELISA: TNF-α, IL-6↓ | — |
CMS model [185, 186]. Oral administration of baicalin (20, 40 mg/kg/day) for 3 weeks significantly improved sucrose intake, locomotor activities, and behavioral despair in CMS rats. The mechanism of baicalin against CMS-induced depression was partially achieved by increasing levels of DCX, neuron-specific enolase (NSE), and BDNF, reducing oxidative stress, and modulating the GSK3/NF-κB/NLRP3 signal cascade in the HIP [185]. In addition, baicalin supplementation (30, 60 mg/kg/day, p.o.) for 3 weeks also inhibited TLR4 activation and pro-inflammatory cytokine secretion in CMS mice. Furthermore, it was confirmed that the inhibition might be realized through PI3K/AKT/FoxO1 pathway in LPS-stimulated BV2 cells [186]. Quercetin is a flavanol present in apples, onions, and berries [37]. Treatment with quercetin (40, 80 mg/kg/d, p.o.) for 2 weeks significantly reversed OBX-induced increase in immobility time in the FST, possibly by inhibiting TNF-α, IL-6, and caspase-3.

### Table 2 (continued)

| Treatment                     | Animal models | Behavioral test | Analyzed regions | Microglia | Pro-inflammatory | Anti-inflammatory |
|-------------------------------|---------------|-----------------|------------------|-----------|-----------------|------------------|
| Theaflavins [246]             | LPS           | TST             | HIP              | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ downregulated | ELISA: TNF-α, IL-1β ↑ | —                |
| Epigallocatechin-3-gallate [99]| LPS           | —               | HIP              | Iba-1 ↑ mRNA: IL-6, TNF-α ↓, IL-1β ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Gypenosides [192]             | CMS           | SPT, TST        | HIP              | mRNA: IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Kosonan [237]                 | CSDS          | Social avoidance test | HIP              | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Aquilariae Lignum ethanol extracts [238] | CRS         | —               | HIP              | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Rosemary Extracts [239]       | CRS           | OFT, TST, FST   | Serum            | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Radix Polygalae extract [240] | CRS           | OFT, SPT, NSFT  | PFC              | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Bangpungtong-sang-san [241]   | Reserpine     | OFT, TST, FST   | HIP              | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| XingnaoJieyu decoction [242]  | MCAO+CMS      | OFT, FST        | Cortex           | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Ganoderma lucidum polysaccharides [243] | CSDS       | OFT, SPT, TST, FST | HIP              | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Water extract of Armillaria mellea (Vahl) P. Kumm [244] | CMS | OFT, FST        | Cerebral         | mRNA: IL-1β, IL-6, TNF-α ↓, Iba-1 ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Xiaooyaosan [245]             | CMS           | SPT, OFT, FST, NSFT | HIP              | mRNA: COX-2 ↓, IL-1β, IL-6, IL-10 upregulated, BDNF ↑ | ELISA: TNF-α, IL-1β ↓ | —                |
| Myelophil [96]                | CMS           | OFT, TST, FST   | HIP              | mRNA: COX-2 ↓, IL-1β, IL-6, IL-10 upregulated, BDNF ↑ | ELISA: TNF-α, IL-1β ↓ | —                |

↑ upregulated; ↓ downregulated; (–) no significant difference; — no explicit data
in the HIP and cortex. Co-treatment with minocycline (25 mg/kg, p.o.) significantly potentiated its protective effects when compared to treatment with quercetin alone [187]. Treatment with quercetin (40 mg/kg/day, p.o.) for 2 weeks alleviated depressive-like behavior in the SPT and FST of LPS-challenged rats via regulation of BDNF-related imbalance of Copine 6 and TREM1/2 in the HIP and PFC [188].

Terpenoids
Terpenoids, especially triterpenoids, monoterpenes and sesquiterpenes, are the most abundant natural compounds found in several vegetables and fruits. Recently, some terpenoids have been reported to have preventive efficacy against neurological diseases by modulating the activation of microglia, especially on depression. Saponins, which are triterpene glycosides, are abundant in some plants, and their general biological activities have been summarized [189]. Saikosaponin-D is a triterpenoid saponin derived from *Radix bupleuri* and exhibits anti-inflammatory, anti-oxidative, and other pharmacological activities [190]. Previous studies have suggested that treatment with saikosaponin-D (0.75, 1.50 mg/kg/day, p.o.) for 3 weeks remarkably ameliorated the CMS-induced depressive-like behaviors in rats, mainly by improving HPA axis functions and hippocampal neurogenesis [191]. Moreover, additional research confirmed that saikosaponin-D administration ameliorated LPS-induced depressive-like behaviors, as shown by increased sucrose consumption in the SPT and decreased immobility time in the TST and FST. These performances appear to be mediated by inhibition of microglial activation and regulation of the high mobility group box 1 (HMGB1)/TLR4/NF-κB signaling pathway [190]. Gypenosides, the major ingredients of *Gynostemma pentaphyllum*, exert a neuroprotective function in the CNS. Treatment with gypenosides (50, 100 mg/kg/day, p.o.) for 4 weeks significantly relieved depressive-like behaviors of CMS mice in the TST and FST, which was mediated, in part, by inhibiting microglial activation and NF-κB signaling and increasing BDNF levels in the HIP [192, 193].

Ginsenosides are one of *ginseng*’s most biologically active ingredients and have a triterpenoid glycoside structure [194]. Direct and indirect evidence support that some ginsenosides (such as ginsenoside Rg3, Rb1, and Rg1) induce the anti-inflammatory actions of macrophages and microglia [195]. Ginsenoside Rb1 is a typical 20(S)-protopanaxadiol-type saponin and exerts significant antidepressive effects in chronic stress models [73, 196, 197]. It is known that Rb1 regulates microglial activation, protects neurons from inflammatory and oxidative damage, and promotes neurogenesis [198, 199]. Recently, treatment with Rb1 (20 mg/kg/d, p.o.) in CMS-treated mice for consecutive 4 weeks alleviated depressive-like behaviors in the SPT, TST, and FST mainly through PPARγ-mediated transitions in microglial phenotype (TNF-α, IL-1β, TGF-β, and Arg-1) in the HIP and cortex [73]. Rb1 attenuated a decrease in BDNF and the ratio of p-AKT/AKT expression, and increased IL-1β, TNF-α, and Iba-1 levels in the HIP in a CRS model. In line with in vivo reports, Rb1 lowered the protein expressions of IL-1β and TNF-α in BV-2 cells [197]. In addition to Rb1, ginsenoside Rg1 and Rg3 exhibited potential anti-inflammatory effects, which protected against microglial activation in stress-injured rodents [200, 201]. A previous study reported that chronic pretreatment with ginsenoside Rg1 (40 mg/kg/d, i.p.) for 5 weeks significantly suppressed inflammatory responses by alleviating microglial and astrocyte activation through decreased overexpression of IL-1β, IFN-γ, and TNF-α. These effects were accompanied by attenuation of dendritic spine and synaptic defects, and upregulation of synaptic-related proteins in the ventral medial prefrontal cortex (vmPFC). Ginsenoside Rg1 inhibited neuronal apoptosis by increasing Bcl-2 and decreasing cleaved caspase-3 and caspase-9 expressions after CMS exposure. Furthermore, ginsenoside Rg1 increased the nuclear factor erythroid 2-related factor (Nrf2) and inhibited p38 mitogen-activated protein kinase (p-p38 MAPK) and p65-NF-κB activation in the vmPFC [200]. Moreover, ginsenoside Rg3 at oral doses of 20 and 30 mg/kg attenuated upregulation of TNF-α, IL-1β, and IL-6 mRNA expression in brains of C57BL/6 mice after systemic LPS injection. Morphological activation of microglia, and Iba-1, cyclooxygenase-2 (COX-2), iNOS protein expression was reduced with Rg3 treatment [201]. Our previous studies also found that ginsenosides Rd and Re (10, 20, or 40 mg/kg, p.o.) have potentially neuroprotective and anti-inflammatory properties, as manifested by significantly reducing the expression of hippocampal pro-inflammatory factors and NLRP3 inflammasome related protein, as well as enhancing endogenous antioxidant factor Nrf2, and mediating PI3K-AKT and BDNF signaling pathways in mice exposed to CRS [129, 202]. Taken together, the anti-inflammatory effects of ginsenosides have been confirmed, and the negative regulation of pro-inflammatory cytokines and enzymes has been found to underlie the anti-inflammatory properties of ginsenosides in pro-inflammatory microglia in depression. However, additional studies are needed to investigate whether other ginsenosides or their metabolites can relieve depressive symptoms through modulating microglial phenotype and the molecular mechanisms involved in neuroinflammation.
Iridoid glycosides
Catalpol, an iridoid glucoside, is primarily isolated from *Radix rehmannia* and is commonly used as a traditional Chinese medicine [203]. Previous studies have been reported that catalpol exhibits a wide range of pharmacological effects, including exhibiting anti-diabetic, anti-tumor, anti-inflammatory, and antioxidant activities. Growing evidence indicates that catalpol has a robust antidepressant effect that acts through its anti-inflammatory and anti-oxidative properties in vitro and in vivo [203, 204]. Catalpol (5, 10, or 20 mg/kg/day, i.g.) administration for 5 weeks ameliorated CMS-induced depressive-like behavior in the SPT, and its underlying mechanisms might be at least partially ascribed to reducing HPA axis dysfunction, upregulating BDNF and its specific binding receptor tyrosine kinase B (TrkB), down-regulating COX-2 expression, thus reducing prostaglandin E2 level in the brain [204]. It was also confirmed that catalpol at 20 mg/kg decreased the expression of NLRP3 inflammasome-associated proteins and inhibited pro-inflammatory microglial polarization in the HIP (IL-1β, TNF-α, and iNOS) [205]. Geniposide, a type of iridoid glycoside extracted from the ripe fruit of *Gardenia jasminoides* Ellis, exhibits numerous bioactivities, including anti-diabetic, anti-oxidative, and anti-inflammatory actions [206]. It has been demonstrated that administration of geniposide (10, 40 mg/kg/day, p.o.) for 1 or 3 weeks ameliorated LPS- and CMS-induced depressive-like behavior in the SPT, and CST by regulating the Bruton’s tyrosine kinase (ATK)/TLR4/NF-κB, BDNF/TrkB, and BTK/JAK2/STAT1 signaling pathways [207, 208]. Also, the beneficial effect of geniposide on anxiety- and depressive-like behaviors in mice may possibly act through induction of microglial polarization towards anti-inflammatory phenotype and inhibition of IL-6 and TNF-α release [208].

Phenylpropanoids
Arctigenin and its glycoside, arctiin, are the major active ingredients of the dried ripe fruit of *Arctiumlappa* L. Arctiiin can be metabolized into arctigenin by human intestinal microflora after oral consumption [209]. Arctiin has antidepressive effects that appear to act through inhibition of the NF-κB mediated HMGB1/TLR4 and TNF-α/TNF receptor 1 (TNFR1) pathways, which consequently attenuated microglial activation and neuroinflammation [210]. Similarly, arctigenin showed antidepressive effects by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFFR1/NF-κB signaling pathways [171]. Salvanolic acid B (SalB) is one of the phenolic acid compounds derived from *Salvia miltiorrhiza*, which has various pharmacological effects, including anti-inflammatory, antioxidant, and anti-apoptotic [211, 212]. CMS mice treated with SalB (20 mg/kg/day, i.p.) for 3 weeks significantly reversed decreased sucrose preference index in the SPT and increased immobility time in the FST and TST. In addition, the decreased expression of IL-1β and TNF-α and increased expression of IL-10 and TGF-β were accompanied by increased apoptosis (cleaved-caspase 3⁺) and microglial activation (Iba-1⁺) in the HIP and cortex that were reversed after SalB treatment [213]. Curcumin is a representative natural phenolic compound of turmeric and a potential candidate for regulation of brain function due to its antioxidant and anti-inflammatory properties. In a CRS model, systemic administration of curcumin (10, 20, or 30 mg/kg, i.p.) daily for 3 weeks significantly attenuated oxidative stress and lipid peroxidation, prevented apoptosis, and increased antioxidant defense activity [214]. Curcumin (10 mg/kg, i.p.) also was beneficial for maintaining improved memory and mood functions after 30 days of daily therapy in a Gulf War Illness (GWI) with stress-treatment model. At the molecular level, enhanced numbers of DCX⁺ cells, decreased numbers of Iba-1/ED-1⁺ cells, and elevated antioxidant genes with normalized mitochondrial respiration might be the basis of the regulatory mechanism that is mediated by curcumin treatment [215]. Magnolol, a hydroxylated biphenyl compound extracted from Magnolia tree, has endothelial cell protective, antioxidant, and anti-inflammatory functions [216]. It is noteworthy that magnolol exhibits antidepressant effects, as evident by increased sucrose consumption and decreased the immobility time in the SPT, TST, and FST. In an OBX model, magnolol (50, 100 mg/kg/day, p.o.) treatment for 2 weeks produced antidepressant-like effects by enhancing neurogenesis (as indicated by BrdU positive cells) in the HIP [217]. In a CMS model, treatment with magnolol (20, 40 mg/kg/day, p.o.) for 4 weeks increased BDNF expression and normalized serotonergic system [218]. In agreement with previous studies, the protective effect of magnolol (50, 100 mg/kg/day, p.o.) given for 3 weeks to CMS-treated female mice also appeared to be associated with inhibition of pro-inflammatory microglia (TNF-α, IL-1β, and IL-6) and activation of anti-inflammatory microglia (IL-4, IL-10, Arg1, Ym1, Fizz1, and Klf4) via Nrf2/hemeoxygenase (HO-1)/NLRP3 signaling pathway [219].

Others
Resveratrol is one of the most well-known dietary stilbenoids. Resveratrol confers health benefits due to its antioxidant, anti-inflammatory, anti-aging, and immune-regulatory activities [220]. Resveratrol is found in the skin of red grapes, peanuts, and other medicinal plants. Recent studies have found that resveratrol ameliorated depressive-like behaviors in several animal models
[221–223]. In a LPS model, mice were treated for 2 weeks with resveratrol (20 mg/kg/day, i.p.), which abrogated the increased immobility in the FST and TST. Immunohistochemical staining revealed that resveratrol reversed increased microglial activation (Iba-1+) and inhibition of neurogenesis (BrdU/DCX+) in the DG [224]. Moreover, 3 doses of resveratrol (20 mg/kg/day, i.p.) promoted the activation of sirtuin type 1 and blocked the decline of hippocampal neurogenesis triggered by ethanol exposure during early postnatal life [225]. The carotenoids crocin was able to regulate microglial activation associated with neurological disorders. Crocin decreased the expression of LPS-induced NO, TNF-α, and ROS production in BV-2 cells and improved locomotor activity, sucrose intake, and reduced immobility time in LPS-treated Kunming mice [226]. The health benefits associated with crocin might be due to its potent ability to regulate the NLRP3 inflammasome and NF-kB, as well as anti-inflammatory phenotypic conversion [226]. Moreover, emerging data have shown that plant-derived compounds can exert neuroprotective effects that prevent neurological disorders in depression. For instance, ganoderic acid A [227], asperosaponin VI [228], 20(S)-protopanaxadiol [229], scutellarin [230], astragalin [231], hesperidin [232], 5-O-methylvisammioside [233], ginkgolide B [234], leonurine [235], ferulic acid [236], and (+)-sesamin [69] were found to inactivate microglia in stress-induced depression models. Recent information concerning the antidepressant activity of phytochemicals through regulation of microglial polarization is illustrated in Table 2. In addition, several herbal extracts and traditional formulations reported to improve depression-like behavior by regulating microglia are shown in Table 2 [237–245].

Conclusions
This review has summarized the current knowledge regarding microglial activation in depression as seen in clinical and preclinical studies. Microglia are the primary resident immune cells that are currently considered as a critical link between neurological and immunological activity in the CNS [247]. These cells modulate neuronal function not only during an inflammatory response, but also during developmental synaptic pruning and plasticity in healthy brains [27]. The heterogeneous states of activated microglia exist on a continuum ranging from neuroprotection to neurotoxic/pathogenic activity (Figs. 1 and 2) [248]. In this review, we summarized microglial activation in depressed patients and animal models (Additional file 1: Table S1), as well as the possible mechanisms associated with the pathogenesis of MDD (Fig. 4). Moreover, we described the therapeutic role of traditional antidepressants and phytochemicals in stress-induced depression models (Tables 1 and 2).

Recently, natural compounds have been considered to be potential agents for the prevention or treatment of neuropsychiatric diseases due, in part, to their antioxidant and anti-inflammatory activities [249]. Numerous studies have shown that natural compounds and formulations are beneficial in the treatment of depression through their ability to regulate microglial functions, as listed in Table 2. The chemical structures of these bioactive compounds are highlighted in Fig. 5. Most compounds have been shown to modulate inflammatory response, oxidative stress, and ameliorate symptoms of depression through inhibiting microglial activation. However, additional research is needed to determine whether these compounds promote the transformation of microglia with a pro-inflammatory phenotype to an anti-inflammatory phenotype, or whether they depend on regulation of downstream signaling pathways that are activated by microglia. In a pathological state, changes in microglial phenotypes depend on the disease stage and severity. Therefore, developing protocols that control the stage-specific conversion of pro-inflammatory/anti-inflammatory actions in appropriate time frames might provide better therapeutic outcomes. Thus, changing the activity of microglia to a stable state through pharmacological or non-pharmacological methods will be the focus of future research, which also may provide new ideas for targeted treatment of depression. Moreover, it has been shown that some polyphenolic compounds are not completely absorbed via the gastrointestinal tract but still possess anti-inflammatory actions due to metabolites that are produced by intestinal microflora [250]. However, information concerning the role of these activated metabolites through microglial regulation is still minimal. Therefore, the discovery of potential inhibitors against microglial activation from metabolites may also be another promising strategy for the prevention of depression in the future.

In addition, data primarily obtained from studies that used specific microglial manipulation methods help improve our understanding of the mechanisms underlying neurogenesis, inflammation, and neurotransmitter metabolism dysfunction in depression. Genetic and pharmacological methods that directly or indirectly modify the activation status of microglia have been used and achieved some success, such as the Cx3cr1−/− or Cd200-deficient mouse models and the minocycline or PLX4497 treatment mouse models [75, 251]. Moreover, it should be noted that the dichotomy of microglial activation states (M1/M2) is an oversimplified conceptual framework. This dichotomy is not generally accepted as it may not accurately reflect the heterogeneous microglial profiles that can be observed in complicated homeostatic or disease conditions [252–254]. The spatial and temporal
The distribution of microglial subsets can be better assessed using newly developed unbiased and high-throughput methods. Novel single-cell techniques enable scientists to overcome such limitations and reveal the surprising context-dependent heterogeneity of microglia [247, 255]. Specific subsets and key targets of microglia have been revealed in the development of AD and regulators such as TREM2 that control disease severity has been identified [42]. Currently, advanced technologies and tools are being used to comprehensively decipher the role of microglial heterogeneity in the pathology of depression, particularly in the modulation, inhibition, and stimulation of contextually relevant microglia functions. These technologies also are being used to target microglia to explore the treatment of neuropsychiatric diseases, which remains to be explored further.

Taken together, the data analyzed in this review suggest that microglial changes mainly affect the regulation of inflammatory response, neurogenesis, and tryptophan metabolism with respect to the development of depression. However, other factors should not be ignored. The discovery of natural compounds that exert antidepressant effects by inhibiting microglial activation may contribute to the effectiveness of preventing and treating depression. Additional information regarding the neuroprotective properties of these compounds that act through the regulation of microglial phenotypes remains to be explored in the future. High-performance omics technologies are expected to provide more effective molecular targets and identify additional specific signaling pathways in drug screening and disease diagnosis.
Fig. 5 Chemical structures of several plant-derived natural compounds that act as potential inhibitors of M1-type microglia activation in animal models of depression
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12974-022-02492-0.

Additional file 1: Table S1. The animal models of depression involving microglial changes.

Acknowledgements

The authors would like to thank the Hotchkiss Brain Institute, the National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, and Natural Sciences and others for their financial contributions. The authors have no competing financial interests with respect to the work described here. All figures were generated with BioRender and ChemDraw.

Author contributions

All authors participated in writing the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Beijing Young Top-Notch Talent Support project (20180000212232K36), Beijing Talents Project (2020438), Beijing Hospitals Authority Youth Programme (QML20181901), National Natural Science Foundation of China (82171526 and 31970918), Beijing Biobank of Clinical Resources-Mental Disorders (BBCR-MD), and Beijing Municipal Administration of Hospitals Incubating Program (PX2018065).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.
18. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Lyengar RL, Mors O, 
et al. Effect of anti-inflammatory treatment on depression, depressive 
symptoms, and adverse effects. A systematic review and meta-analysis of 
 randomized controlled trials. JAMA Psychiat. 2014;71:1381–91.
19. Pae CU, Marks DM, Han C, Park AA. Does minocycline have anti-de-
presant effect? Biomed Pharmacother. 2008;62:308–11.
20. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard 
et al. Altered M1/M2 activation patterns of monocytes in severe 
relapsing experimental rat model of multiple sclerosis. Amelioration of 
clinical status by M2 activated monocyte administration. Mult Scler. 
2011;17:2–15.
21. Pusic KM, Pusic AD, Kemme J, Kraig RP. Spreading depression requires 
microglia and is decreased by their M2a polarization from environmen-
tal enrichment. Gla. 2014;62:1176–94.
22. Nakagawa Y, Chiba K. Role of microglial M1/M2 polarization in relapse 
and remission of psychiatric disorders and diseases. Pharmaceuticals 
(Basel). 2014;7:1028–48.
23. Zhang L, Zhang QJ, You ZL. Switching of the microglial activation 
phenotype is a possible treatment for depression disorder. Front Cell 
Neurosci. 2018;12:306.
24. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or 
something else? Science. 2013;339:156–61.
25. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution 
and morphology of microglia in the normal adult mouse brain. Neuro-
science. 1990;39:151–70.
26. Gnhnowx F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate 
mapping analysis reveals that adult microglia derive from primitive 
macrophages. Science. 2010;330:841–5.
27. Wright-Jin EC, Gutmann DH. Microglia as dynamic cellular mediators of 
brain function. Trends Mol Med. 2019;25:967–79.
28. Kanazawa M, Ninomiya I, Hatakeyama M, Takahashi T, Shimohata T. 
Microglia and monocytes/macrophages polarization reveal novel 
therapeutic mechanism against stroke. Int J Mol Sci. 2017;18:2135.
29. Rock RB, Gekker G, Hu S, Sheng WS, Cheever K, Lokensgard JR, et al. 
Role of microglia in central nervous system infections. Clin Microbiol 
Rev. 2004;17:942–64.
30. Jurga AM, Paleczna M, Kuter KZ. Overview of general and discriminat-
ing markers of differential microglia phenotypes. Front Cell Neurosci. 
2020;14:198.
31. Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and 
morphological and metabolic states. Br J Pharmacol. 2016;173:649–65.
32. Calcia MA, Bonsall DR, Bloomfield PS, Selvaraj S, Barichello T, Howes OD. 
Stress and neuroinflammation: a systematic review of the effects of 
stress on microglia and the implications for mental illness. Psychophar-
macology. 2016;233:1637–50.
33. Dibaj P, Nadirigny J, Steffens H, Scheller A, Hirlinger J, Schomburg ED, 
et al. NO mediates microglial response to acute spinal cord injury under 
ATP control in vivo. Gla. 2010;58:1133–44.
34. Steiner J, Walter M, Gos T, Guillemin GJ, Newman L, Farmer C, 
et al. Spatial and temporal heterogeneity of mouse and human 
macrophages. Science. 2010;330:841–5.
35. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefron-
tal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:15290–5.
36. Calcia MA, Paleczna M, Kuter KZ. Reductions in neuronal and glial 
density characterize the dorsolateral prefrontal cortex in bipolar disor-
der. Biol Psychiatry. 2001;49:741–52.
37. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Melzer 
HJ, et al. Morphometric evidence for neuronal and glial prefrontal cell 
density in major depression. Biol Psychiatry. 2010;68:1–7.
38. Cotter D, Mackay D, Landau S, Kervin R, Everal I. Reduced glial cell 
density and neuronal size in the anterior cingulate cortex in major 
depressive disorder. Arch Gen Psychiatry. 2001;58:545–53.
39. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the 
amygdala in major depressive disorder. Biol Psychiatry. 2002;52:404–12.
40. Ongur D, An X, Price JL. Prefrontal corticostriatal projections to the hypothala-
mus in macaque monkeys. J Comp Neurol. 1998;401:480–505.
41. Sousa C, Golebiewska A, Poovathaling SK, Kaoma T, Pires-Afonso Y, 
Martina S, et al. Single-cell transcriptomics reveals distinct inflamma-
tion-induced microglia signatures. EMBO Rep. 2018;19: e46171.
42. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-
Sternfeld R, Ullanid TK, et al. A unique microglia type associ-
ated with restricting development of Alzheimer’s Disease. Cell. 
2017;169:1276–90.
43. Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Nagar 
et al. Spatial and temporal heterogeneity of mouse and human 
microglia at single-cell resolution. Nature. 2019;566:388–92.
44. Liu H, Sagar AP, Keri S. Translocator protein (18kDa TSPO) binding, 
a marker of microglia, is reduced in major depression during cognitive-
behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 
2018;83:1–7.
45. Setiawan E, Attwell S, Wilson AA, Mizrahi R, Rusjan PM, Miller L, 
et al. Role of translocator protein density, a marker of neuroinflam-
mation, in the brain during major depressive episodes. JAMA Psychiat. 
2015;72:268–75.
63. Tetreault NA, Hakreem AF, Jiang S, Williams BA, Allman E, Wold BJ, et al. Microglia in the cerebral cortex in autism. J Autism Dev Disorders. 2012;42:2569–84.
64. Zhang Y, Su WJ, Chen Y, Wu TY, Gong H, Shen XL, et al. Effects of hydrogen-rich water on depressive-like behavior in mice. Sci Rep. 2016;6:23742.
65. Liu LL, Li JM, Su WJ, Wang B, Jiang CL. Sex differences in depressive-like behaviour may relate to imbalance of microglia activation in the hippocampus. Brain Behav Immun. 2019;81:188–97.
66. Sugama S, Takenouchi T, Fujita M, Comti B, Hashimoto M. Differential microglial activation between acute stress and lipopolysaccharide treatment. J Neuroimmunol. 2009;207:24–31.
67. Tyan RJ, Nacser S, Hinwood M, Nailvaiko E, Buller KM, Pow DV, et al. Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun. 2010;24:1058–68.
68. Wohlbeg ES, Fenn AM, Pacenta AM, Powell ND, Sheridan JF, Godbout JP. Peripheral innate immune challenge exaggerates microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology. 2012;37:1491–501.
69. Zhao YH, Wang QX, Jia MZ, Fu Z, Pan JR, Chu CQ, et al. (+)-Sesamin attenuates chronic unpredictable mild stress-induced depressive-like behaviors and memory deficits via suppression of neuroinflammation. J Nutr Biochem. 2019;64:61–71.
70. Arizó BI, Tastan B, Tarakcioglu E, Tufekci KU, Olcum M, Ersoy N, et al. Metatonin attenuates LPS-induced acute depressive-like behaviors and microglial NLRP3 inflammasome activation through the SIRT1/Nrf2 pathway. Front Immunol. 2019;10:1511.
71. Xu Y, Xu YZ, Wang YR, Wang YJ, He L, Jiang ZZ, et al. Telmisartan prevents LPS-induced microglia polarization via CaMKKβ-dependent AMPK activation. Brain Behav Immun. 2015;50:298–313.
72. Zhang JW, Zheng YL, Luo Y, Du Y, Zhang XJ, Fu JL. Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/TLR4/NF-κB pathways in BV2 cells. Mol Immunol. 2019;116:29–37.
73. Zhang LJ, Tang MM, Xie XF, Zhao QY, Hu N, He H, et al. Ginsenoside Rb1 induces a pro-inflammatory microglial phenotype via PPARγ activation in male mice exposed to chronic mild stress. J Neuroinflammation. 2021;18:171.
74. Lehmann ML, Weigel TK, Poffenberger CN, Herkenham M. The behavioral sequelae of social defeat require microglia and are driven by oxidative stress in mice. J Neurosci. 2019;39:5594–605.
75. Chamera K, Troján E, Szuster-Gluszczak M, Basta-Kaim A. The potential role of dysfunctions in neuron-microglia communication in the pathogenesis of brain disorders. Curr Neuropharmacol. 2020;18:408–30.
76. Liu Y, Wu XM, Luo QQ, Huang S, Yang Q-WQ, Wang FX, et al. CX3CL1/CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK/PKC pathway. J Cereb Blood Flow Metab. 2015;35:1623–31.
77. Zanier ER, Marchesi F, Orlotolo F, Perego C, Arabian M, Zoerle T, et al. Fractalkine receptor deficiency is associated with early protection but Fractalkine receptor deficiency impairs microglial and neuronal responsive- ness to chronic stress. Brain Behav Immun. 2016;55:114–25.
78. Frank MG, Forken LJ, Kook AD, Anghelescu DP, Workik EE, Laufer SF. Stress disinhibits microglia via down-regulation of CD200R: a mechanism of neuroinflammation priming. Brain Behav Immun. 2018;69:62–73.
79. Forken LJ, Frank MG, Gaudet AD, D’Angelo HM, Daut RA, Hampson EC, et al. Neuroinflammatory priming to stress is differentially regulated in male and female rats. Brain Behav Immun. 2018;70:257–67.
80. Blandino P, Barnum CJ, Solomon LG, Larish Y, Lankow BS, Deak T. Gene expression changes in the hypothalamus provide evidence for regionally-selective changes in IL-1 and microglial markers after acute stress. Brain Behav Immun. 2009;23:958–68.
81. Wachholz S, Ellinger M, Plümper J, Maintz MP, Juckel G, Friebe A. Microglia activation is associated with IFN-α induced depressive-like behavior. Brain Behav Immun. 2016;55:105–13.
82. Nieto-Quero A, Chaves-Peña P, Santín LJ, Pérez-Martín M, Pedraza C. Do changes in microglial status underlie neurogenesis impairments and depressive-like behaviours induced by psychological stress? A systematic review in animal models. Neurobiol Stress. 2021;15:100356.
83. Anacker C, Luna VM, Stevens GS, Millette A, Shores R, Jimenez JC, et al. Hippocampal neurogenesis confers stress resilience by inhibiting the ventral dentate gyrus. Nature. 2018;559:98–102.
84. Ito N, Nagai T, Yabe T, Nunome S, Hanawa T, Yamada H. Antidepressant-like activity of a Kampo (Japanese herbal) medicine, Koso-san (Xiang- Su-San), and its mode of action via the hypothalamic-pituitary-adrenal axis. Phytomedicine. 2006;13:658–67.
85. Lu M, Yang JZ, Geng F, Ding JH, Hu G. Iptakalim confers an antide- pressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis. Int J Neuropsychopharmacol. 2014;17:1501–10.
86. Schoenfeld TJ, Gould E. Stress, stress hormones, and adult neurogen- esis. Exp Neurol. 2012;233:12–21.
87. Lee JS, Kim WJ, Jeon YS, Lee SB, Lee DS, Son CG. Antidepressant-like activity of Myophelium attenuation of microglial-mediated neuroinflammation in mice undergoing unpredictable chronic mild stress. Front Pharmacol. 2019;10:683.
88. Llorens-Martín M, Jurado-Aronja J, Bolós M, Pallás-Bazana N, Ávila J. Forced swimming sabotages the morphological and synaptic matura- tion of newborn granule neurons and triggers a unique pro-inflammatory milieu in the hippocampus. Brain Behav Immun. 2016;53:242–54.
89. Ekdaal CT, Claassen JH, Ronde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003;100:13652–7.
90. Seong KJ, Lee HG, Kook MS, Ko HM, Jung JY, Kim WJ. Epigallocatechin-3-gallate rescues LPS-impaired adult hippocampal neurogenesis through suppressing the TLR4-NF-κB signaling pathway in mice. Korean J Physiol Pharmacol. 2016;20:41–51.
91. Cheng J, Chen M, Zhu JX, Lu CF, Zhang QP, Geng D, et al. FGF-2 signaling activation in the hippocampus contributes to the behavioral and cel- lular responses to puerarin. Biochem Pharmacol. 2019;168:91–9.
101. Vega-Rivera NM, Ortiz-López L, Granados-Juárez A, Estrada-Camarena EM, Ramírez-Rodríguez GB. Melatonin reverses the depression-associated behaviour and regulates microglia, fractalkine expression and neurogenesis in adult mice exposed to chronic mild stress. Neurosci. 2020;440:316–36.

102. Zhang JQ, Xie XF, Tang MM, Zhang J, Zhang BY, Zhao QY, et al. Salvinorin A 8 promotes microglial M2-polarization and rescues neurogenesis in stress-exposed mice. Brain Behav Immun. 2017;66:111–24.

103. Han Y, Zhang LJ, Wang QZ, Zhang DD, Zhao QY, Zhang JQ, et al. Minocycline inhibits microglial activation and alleviates depressive-like behaviors in infant and adolescent mice subjected to maternal separation. Psychooncology. 2019;17:37–45.

104. Zhao QY, Peng C, Wu XH, Chen YR, Wang C, You ZL. Maternal sleep deprivation inhibits hippocampal neurogenesis associated with inflammatory response in young offspring rats. Neurobiol Dis. 2014;68,57–65.

105. Mao ZF, Ouyang SH, Zhang QY, Wu YP, Wang GE, Tu LF, et al. New insights into the effects of caffeine on adult hippocampal neurogenesis in stressed mice: inhibition of CORT-induced microglia activation. FASEB J. 2020;34:10998–1014.

106. Jiang N, Lv JW, Wang HX, Lu C, Wang Q, Xia TJ, et al. Dammarane sapogenins alleviates depression-like behaviours induced by chronic social stress in mice through the promotion of the BDNF signalling pathway and neurogenesis in the hippocampus. Brain Res Bull. 2019;153:239–49.

107. Jiang N, Lv J, Wang HX, Huang H, Wang Q, Lu C, et al. Ginsenoside Rg1 ameliorates chronic social stress-induced depressive-like behaviors and hippocampal neuroinflammation. Life Sci. 2020;252: 117669.

108. Park JH, Shim HS, An K, Starkweather A, Kim KS, Shim I. IL-4 inhibits IL-1β-induced depressive-like behavior and central neurotransmitter alterations. Mediators Inflamm. 2015;2015: 941413.

109. Butovskiy O, Ziv Y, Schwartz A, Landi G, Tallparter AE, Pluchino S, et al. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci. 2006;31:149–60.

110. Forster R, Sarginson A, Velichkova A, Hogg C, Dorning A, Horne AW, et al. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. J Neuroinflammation. 2017;14:102.

111. Zhang Y, Liu L, Peng YL, Liu YZ, Wu TY, Shen XJ, et al. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int J Neuropsychopharmacol. 2015;18(8):pyo006.

112. Yue N, Huang HJ, Zhu XC, Han QQ, Wang YL, Li B, et al. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. J Neuroinflammation. 2017;14:102.

113. Zhang Y, Liu L, Peng YL, Liu YZ, Wu TY, Shen XJ, et al. Involvement of NLRP3 inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci Ther. 2014;20(2):119–24.

114. Dai JJ, Ding ZF, Zhang J, Xu W, Guo QL, Zou WW, et al. Minocycline relieves depressive-like behaviors in rats with bone cancer pain by inhibiting microglia activation in hippocampus. Anesth Analg. 2019;129:1733–41.

115. Arakawa S, Shirayama Y, Fujita Y, Ishima T, Horio M, Muneoka K, et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Biotechnol Biochem. 2012;100:601–6.

116. Liu L, Li JD, Dai P, Zhao F, Zheng G, Jing JF, et al. Microglia activation regulates GluR1 phosphorylation in chronic unpredictable stress-induced cognition dysfunction. Stress. 2015;18:96–106.

117. Wang HX, Lv JW, Jiang N, Huang H, Wang Q, Liu X. Ginsenoside Re inhibits microglial NLRP3 inflammasome activation and regulation of inflammation induced by chronic stress in mice. Biomed Res Int. 2015;2015:35235–35.

118. Du RH, Tan J, Sun XY, Lu M, Ding JH, Hu G. Fluoxetine inhibits NLRP3 inflammasome activation: implication in depression. J Neuropsychopharmacol. 2016;19(9):pyo037.

119. Gong W, Zhang S, Zong Y, Halmi M, Ren Z, Wang Y, et al. Involvement of the microglial NLRP3 inflammasome in the anti-inflammatory effect of the antidepressant clomipramine. J Affect Disord. 2019;254:15–25.

120. Yue N, Li B, Yang L, Han QQ, Huang HJ, Wang YL, et al. Electro-acupuncture alleviates chronic unpredictable stress-induced depressive- and anxiety-like behavior and hippocampal neuroinflammation in rat model of depression. Front Mol Neurosci. 2018;11:149.

121. Garrison AM, Parrott JM, Turton A, Delgado J, Redus L, O’Connor JC. Kynurenine pathway metabolic balance influences microglia: targeting kynurenine metabolism to dampen neuroinflammation. Psychooncology. 2018;94:1–10.

122. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armaiti PJ, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78(4):842–53.

123. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 2002;125:1249–73.

124. Birner A, Platzer M, Bengesser SA, Dalkner F, Fellendorf FT, Queisser R, et al. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder. PloS ONE. 2017;12(2): e0172699.

125. Dantzer R. Role of the kynurenine metabolism in inflammation-induced depression: preclinical approaches. Curr Top Behav Neurosci. 2017;31:117–38.

126. Busse M, Busse S, Myint AM, Gos T, Dobrowolny H, Müller UJ, et al. Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? Eur Arch Psychiatry Clin Neurosci. 2015;265(4):321–9.

127. Oguya K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16–25.

128. Achtenes E, Keaton SA, Smart L, Burmeister AP, Heilman PL, Krzyzanowski S, et al. Inflammation and kynurenine pathway dysregulation in
post-partum women with severe and suicidal depression. Brain Behav Immun. 2020;83:239–47.

141. Öztürk M, Yalın Sarpma S, Kandemir H, Taneli F, Aydemir Ö. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. Int J Clin Pract. 2021;75:e13739.

142. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15:393–403.

143. Metha AA. Decreased levels of the kynurenine metabolic pathway in both the gut and brain. Gut 2013;68:186–94.

144. Thomas J, Khanam R, Vohora D. Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine production and treatment response in major depressive disorder. Int J Clin Pract. 2021;75:e13739.

145. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Learning helplessness activates microglia cells. Cereb Cortex. 2013;23:1645–55.

146. Kopschina Feltes P, Doorduin J, Klein HC, Juárez-Orozco LE, Dierckx MA, Iwata M, Ishida H, Kaneko K, Shirayama Y. Learned helplessness activates microglia M1 markers in the prefrontal cortex of rats and provokes depression-like behaviors. Front Neurosci. 2017;11:209.

147. Burke NN, Kerr DM, Moriarty O, Finn DP, Roche M. Minocycline activates microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. Brain Behav Immun. 2019;81:361–73.

148. Imbeault S, Goiny M, Liu X, Erhardt S. Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation. Acta Neuropathol. 2020;32:43–53.

149. Thomas J, Khaman R, Vohora D. Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine production and treatment response in major depressive disorder. Int J Clin Pract. 2021;75:e13739.

150. Koo YS, Kim H, Park JH, Kim MJ, Shin YI, Choi BT, et al. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism contributes to poststroke depression induced in mice by ischemic stroke along with spatial restraint stress. Oxid Med Cell Longev. 2018;2018:2413841.

151. Fuertig R, Azzinnari D, Bergamini G, Cathomas F, Sigrist H, Seifritz E, et al. Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour. Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase. Brain Behav Immun. 2016;54:59–72.

152. Kopschina Feltes P, Doorduin J, Klein HC, Juárez-Orozco LE, Dierckx MA, Iwata M, Ishida H, Kaneko K, Shirayama Y. Learned helplessness activates microglia M1 markers in the prefrontal cortex of rats and provokes depression-like behaviors. Front Neurosci. 2017;11:209.

153. Xu X, Piao HN, Anaisi F, Zeng XY, Cheng JH, Cui YX, et al. Antidepressant treatmmnt reverses the effects of neonatal immune activation on anxiety-like behaviors via down-regulating inflammatory cytokines induced by chronic restraint stress in mice. Biel Pharm Bull. 2017;40:1260–7.

154. Zhang K, Yang C, Chang LX, Sakamoto A, Suzuki T, Fujita Y, et al. Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Transl Psychiatry. 2020;10:132.

155. Su WJ, Zhang T, Jiang CL, Wang W. Clemastine alleviates depressive-like behavior through reversing the imbalance of microglia-related anti-inflammatory state in mouse hippocampus. Front Cell Neurosci. 2018;12:412.

156. Takahashi K, Nakagawasai O, Nemoto W, Kadota S, Isono J, Odaira T, et al. Memantine ameliorates depressive-like behavior by regulating hippocampal cell proliferation and neuroprotection in olfactory bulbectomized mice. Neuropharmacology. 2018;137:141–55.
178. Yu XB, Zhang HN, Dai Y, Zhou ZY, Xu RA, Hu LF, et al. Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. J Affect Disord. 2019;245:939–49.

179. Nozaki K, Ito H, Ogihara M, Yamauchi Y, Sahin EH, Kitajima T, et al. Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress. Neuropharmacology. 2020;162:107835.

180. Zhao XJ, Zhao Z, Yang DD, Cao LL, Zhang L, Ji J, et al. Activation of ATP-sensitive potassium channel by ippatkalon normalized stress-induced HPA axis disorder and depressive behavior by alleviating inflammation and oxidative stress in mouse hypothalamus. Brain Res Bull. 2017;130:146–55.

181. Zhou SH, Chen SS, Xie WX, Guo XX, Zhao JF. Microglia polarization of hippocampus is involved in the mechanism of Apelin-13 ameliorating chronic cold water immersion restraint stress-induced depression-like behavior in rats. Neuropeptides. 2020;81:102006.

182. Wu B, Song QG, Zhang YK, Wang CS, Yang MQ, Zhang J, et al. Antidepressant activity of ω-3 polyunsaturated fatty acids in ovariectomized rats: role of neuroinflammation and microglial polarization. Lipids Health Dis. 2020;19:4.

183. Guo YX, Gan XH, Zhou HF, Zhou HJ, Pu SY, Long X, et al. Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behavior via affecting microglial and NLRP3 inflammasome activati. Life Sci. 2020;263:118582.

184. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavonanes, and human health: epidemiological evidence. J Med Food. 2005;8:281–90.

185. Zhang CYY, Zeng MJ, Zhou LP, Li YQ, Zhao F, Shang ZY, et al. Baicalin ameliorates hippocampus is involved in the mechanism of Apelin-13 ameliorating chronic water immersion restraint stress-induced depression-like behavior in rats. J Affect Disord. 2019;245:939–49.

186. Guo LT, Wang SQ, Su J, Xu LX, Ji ZY, Zhang RY, et al. Baicalin ameliorates hippocampus is involved in the mechanism of Apelin-13 ameliorating chronic water immersion restraint stress-induced depression-like behavior in rats. Neuropharmacology. 2019;162:107835.

187. Rinwa P, Kumar A. Quercetin suppress microglial neuroinflammatory response and induce antidepressant-like effect in olfactory bulbectomized rats. Neuroscience. 2013;255:86–98.

188. Fang K, Li HR, Chen XX, Gao XR, Huang LL, Du AQ, et al. Quercetin suppresses the chronic unpredictable mild-stress-induced depressive behavior in rats via inhibiting activation of GSK3β/NF-κB/NLRP3 signal pathway in a rat model of depression. Int Immunopharmacol. 2018;64:175–82.

189. Wang YL, Wu HR, Zhang SS, Xiao HL, Yu J, Ma YY, et al. Catalpol ameliorates depressive-like behaviors in CUMS mice via oxidative stress-mediated NLRP3 inflammasome and neuroinflammation. Transl Psychiatry. 2021;11:353.

190. Liu SN, Zheng ML, Li YX, He L, Chen T. The protective effect of Genti- poside on diabetic cognitive impairment through BTK/JAK2/STAT1 pathway. Psychopharmacology. 2020;237:465–77.

191. Chen T, Liu SN, Zheng ML, Li YX, He L. The effect of geniposide on chronic unpredictable mild-stress-induced depressive mice through BTK/JAK2/STAT1 signaling pathway. Phytother Res. 2021;35:932–45.

192. Zheng ML, Li K, Chen T, Shen SN, He L. Geniposide protects depression in rats undergoing chronic unpredictable mild stress. Physiol Behav. 2015;151:360–8.

193. Wang Y, Wang P, Han XY, Wang J, Tan RQ, He F, et al. Simvastatin alleviates LPS-induced depression-like behavior in rats: involvement of HPA axis and hippocampal neurogenesis. Biomed Pharmacother. 2018;106:1141–53.

194. Sonksen P, Mander P, Lee K. Antidepressant-like effect of ginsenoside Rb1 against anxiety and depression-like behaviors in CUMS mice. Brain Behav Immun. 2018;70:30–9.

195. Matsui N, Akae H, Hirashima N, Kido Y, Tanabe S, Koseki M, et al. Magnolol enhances hippocampal neurogenesis and exerts antidepressant-like effects in olfactory bulbectomized mice. J Neurosci. 2016;36:11411–53.

196. Nair SS, Azimiz-Nozad M, Farkhondeh-T, Samanini F. Anti-oxidative and antidepressant-like effects of ginsenoside Rb1 against anxiety and depression-like behaviors in CUMS mice. Brain Behav Immun. 2018;70:30–9.

197. Kodali M, Hattiangady B, Shahidi GA, Bates A, Shuai B, Shetty AK. Curcumin treatment leads to better cognitive and mood function in a model of Gulf War Illness with enhanced neurogenesis, and alleviation of inflammation and mitochondrial dysfunction in the hippocampus. Brain Behav Immun. 2018;69:499–514.

198. Ranaware AM, Banik K, Deshpande V, Patil AV, Patil AV, Patil AV. Curcumin ameliorates depressive-like behaviors in CUMS mice via oxidative stress mediated NLRP3 inflammasome and neuroinflammation. Acta Pharmacol Sin. 2016;37:1141–53.

199. Matsui N, Akae H, Hirashima N, Kido Y, Tanabe S, Koseki M, et al. Magnolol enhances hippocampal neurogenesis and exerts antidepressant-like effects in olfactory bulbectomized mice. J Neurosci. 2016;36:1155–61.

200. Li DW, Zhou FZ, Sun XC, Li SC, Yang JB, Sun HH, et al. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranasal lipopolysaccharide injection. Neuro Regen Res. 2019;14:1814–22.

201. Wang D, Zhao SX, Pan JW, Wang Z, Li Y, Xu XX, et al. Ginsenoside Rb1 attenuates microglia activation to improve spinal cord injury via microRNA-130b-5p/TLR4/NF-κB axis. J Cell Physiol. 2021;236:2144–55.

202. Li HY, Zhao YH, Zeng MJ, Fang F, Li M, Qin TT, et al. Saikosaponin D regulates toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway. J Neuroinflammation. 2019;16:95.

203. Wang JM, Yang LH, Zhang YY, Niu CL, Cui Y, Peng WS, et al. BDNF and Cox-2 participate in antidepressive mechanisms of catalpol in rats undergoing chronic unpredictable mild stress. Physiol Behav. 2020;215:151–60.

204. Wang XJ, Jiang N, Lv JH, Huang H, Liu XM. Ginsenoside Rb2 reverses depressive behavior via inhibiting hippocampal microglia activation following systemic lipopolysaccharide treatment in mice. Acta Pharmacol Sin. 2012;33:1546–52.

205. Wang XJ, Jiang N, Lv JW, Huang H, Liu XM. Ginsenoside Rb2 reverses depressive behavior via inhibiting hippocampal microglia activation following systemic lipopolysaccharide treatment in mice. Acta Pharmacol Sin. 2012;33:1546–52.

206. Wang JM, Yang LH, Zhang YY, Niu CL, Cui Y, Peng WS, et al. BDNF and COX-2 participate in antidepressive mechanisms of catalpol in rats undergoing chronic unpredictable mild stress. Physiol Behav. 2020;215:151–60.

207. Wang XJ, Jiang N, Lv JW, Huang H, Liu XM. Ginsenoside Rb2 reverses depressive behavior via inhibiting hippocampal microglia activation following systemic lipopolysaccharide treatment in mice. Acta Pharmacol Sin. 2012;33:1546–52.

208. Wang JM, Yang LH, Zhang YY, Niu CL, Cui Y, Peng WS, et al. BDNF and COX-2 participate in antidepressive mechanisms of catalpol in rats undergoing chronic unpredictable mild stress. Physiol Behav. 2020;215:151–60.

209. Wang XY, Jiang N, Lv JW, Huang H, Liu XM. Ginsenoside Rb2 reverses depressive behavior via inhibiting hippocampal microglia activation following systemic lipopolysaccharide treatment in mice. Acta Pharmacol Sin. 2012;33:1546–52.
218. Li LF, Lu J, Xi XM, Xu CL, Deng JM, Xu CL, et al. Antidepressant-like effect of magnolol on BDNF up-regulation and serotonergic system activity in unpredictable chronic mild stress treated rats. Phytother Res. 2012;26:1189–94.

219. Tao WW, Hu YW, Chen ZY, Dai YX, Hu Y, Qi MM. Magnolol attenuates depressive-like behaviors by polarizing microglia towards the M2 phenotype through the regulation of NF-κB/HO-1/NLRP3 signaling pathway. Phytomedicine. 2021;91:153692.

220. Navarro G, Martinez-Pinilla E, Ortiz R, Noel V, Ciudad CJ, Franco R. Resveratrol and related stilbenoids, nutraceutical/dietary complements with health-promoting actions: industrial production, safety, and the search for mode of action. Compr Rev Food Sci Food Saf. 2018;17:808–26.

221. Ali SH, Madhana RM, Athira KV, Kasala ER, Boddukur LN, Pitta S, et al. Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice. Steroids. 2015;101:37–42.

222. Ge JF, Peng L, Cheng QJ, Pan CX, Tang J, Chen FH, et al. Antidepressant-like effect of resveratrol: involvement of antioxidant effect and peripheral regulation on HPA axis. Pharmacol Biochem Behav. 2013;114:64–9.

223. Ge L, Liu LW, Liu H, Liu S, Xue H, Wang XE, et al. Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. Eur J Pharmacol. 2015;768:49–57.

224. Liu L, Zhang Q, Cai YL, Sun DY, He X, Wang L, et al. Resveratrol counteracts lipopolysaccharide-induced depressive-like behaviors via enhanced hippocampal neurogenesis. Oncotarget. 2016;7:56045–59.

225. Xu L, Yang Y, Gao LX, Zhao JH, Cai YL, Huang J, et al. Protective effects of resveratrol on the inhibition of hippocampal neurogenesis induced by ethanol during early postnatal life. Biochim Biophys Acta. 2015;1852:298–310.

226. Zhang L, Prevat R, Lu L, Liao RF, Jin Y, Wang RK. Crocin, a natural product attenuates lipopolysaccharide-induced anxiety and depressive-like behaviors through suppressing NF-κB and NLRP3 signaling pathway. Brain Res Bull. 2018;142:352–9.

227. Zhang L, Zeng L, Sun B. Gannoergic acid A-mediated modulation of microglial polarization is involved in depressive-like behaviors and neuroinflammation in a rat model of post-stroke depression. Neuropsychiatr Dis Treat. 2021;17:2671–81.

228. Zhang QJ, Yi SN, Li YH, Xiao CH, Liu C, Jiang WK, et al. The antidepressant effects of asperosaponin VI are mediated by the suppression of microglial activation and reduction of TLR4/NF-κB-induced IDO expression. Psychopharmacology. 2020;237:2331–45.

229. Jiang N, Yu JW, Wang HX, Huang H, Wang Q, Zeng GF, et al. Ginsenoside Rg3-protopanaxadiol attenuates depressive-like behaviour and neuroinflammation in chronic unpredictable mild stress-depressed rats. Behav Brain Res. 2020;393:112710.

230. Ban HT, Wang GH, Huang JJ, Liang L, Xiao L, Wang HL. Scutellaran protects against lipopolysaccharide-induced behavioral deficits by inhibiting neuroinflammation and microglia activation in rats. Int Immunopharmacol. 2020;88:106943.

231. Tong Y, Fu HL, Xia CB, Song W, Li YJ, Zhao J, et al. Astragalin exerts antidepressant-like action through SIRT1 signaling modulated NLRP3 inflammasome deactivation. ACS Chem Neurosci. 2020;11:495–503.

232. Xie LL, Gu ZM, Liu HZ, Jia BT, Wang YY, Cao M, et al. The anti-depressive effects of hesperidin and the relative mechanisms based on the NLRP3 inflammatory signaling pathway. Front Pharmacol. 2020;11:1251.

233. Sun XL, Zhang TW, Zhao Y, Cai EB, Zhu HY, Liu SL. The protective effect of 5-O-methylpisammoside on LPS-induced depression in mice by inhibiting the over activation of BV-2 microglia through NF-κB/NFκB-α pathway. Phytomedicine. 2020;79:153348.

234. Ge YB, Xu W, Zhang LJ, Liu MY. Inhibitory effects of GinkgoB 8 attenuates myocardial infarction-induced depression-like behaviors via repressing RII-B in central nervous system. Int Immunopharmacol. 2020;88:106652.

235. Jia MM, Li CX, Zheng Y, Ding XJ, Chen M, Ding JH, et al. Leunorine exerts antidepressant-like effects in the chronic mild stress-induced depression model in mice by inhibiting neuroinflammation. Int J Neuropsychopharmacol. 2017;20:8866–95.

236. Liu YM, Shen JD, Xu LP, Li HB, Li YC, Yi LT. Ferulic acid inhibits neuroinflammation in mice exposed to chronic unpredictable mild stress. Int Immunopharmacol. 2017;45:128–34.

237. Ito N, Hirose E, Ishida T, Hori A, Nagai T, Kobayashi Y, et al. Kossosan, a Kampo medicine, prevents a social avoidance behavior and attenuates neuroinflammation in socially defeated mice. J Neuroinflammation. 2017;14:98.

238. Lee HY, Lee JS, Kim HG, Kim WR, Lee SB, Choi YH, et al. The ethanol extract of Aqueariae Lignum ameliorates hippocampal oxidative stress in a repeated restraint stress mouse model. BMC Complement Altern Med. 2017;17:397.

239. Guo Y, Xie JP, Li X, Yuan Y, Zhang LC, Hu WY, et al. Antidepressant effects of Rosemary extracts associate with anti-inflammatory effect and re-balancing of gut microbiota. Front Pharmacol. 2018;9:1126.

240. Zhou YF, Yan MZ, Pan R, Wang Z, Tao X, Li CC, et al. Radix Polygalae extract exerts antidepressant effects in behavioral despair mice and chronic stress-induced rats probably by promoting autophagy and inhibiting neuroinflammation. J Ethnopharmacol. 2021;265:113317.

241. Park BK, Kim NS, Kim YR, Yang C, Jung IC, Jiang IS, et al. Antidepressant and anti-neuroinflammatory effects of Bangpungtongsan-San. Front Pharmacol. 2020;11:958.

242. Yan YM, Li J, Wang D, Zhao BB, Zhou Q. Antidepressant effect of Xingnajiao decotion mediated by alleviating neuroinflammation in a rat model of post-stroke depression. J Tradit Chin Med. 2019;39:658–66.

243. Li HR, Xiao YH, Han L, Jia Y, Luo SL, Zhang DD, et al. Ganoderma lucidum polysaccharides ameliorated depression-like behaviors in the chronic social defeat stress depression model via modulation of dectin-1 and the innate immune system. Brain Res Bull. 2021;171:16–24.

244. Lin YE, Wang HL, Lu KH, Huang YJ, Panyod S, Liu WT, et al. Water extract of Armillaria mellea (Vahl) P. Kumm. alleviates the depression-like behaviors in acute- and chronic mild stress-induced rodent models via anti-inflammatory action. J Ethnopharmacol. 2021;265:113395.

245. Jiao HY, Yang HJ, Yan ZY, Chen JB, Xu MB, Jiang YM, et al. Traditional Chinese formula Xiaoyao san alleviates depressive-like behavior in CUMS mice by regulating PEBP1-GPX4-mediated ferroptosis in the hippocampus. Neuropsychiatr Dis Treat. 2021;17:1001–19.

246. Ano Y, Ohya R, Kita M, Taniguchi Y, Kondo K. Theaflavins improve memory impairment and depression-like behavior by regulating microglial activation. Molecules. 2019;24:467.

247. Masuda T, Sankowski R, Staszewski Q, Prinz M. Microglia heterogeneity in the single-cell era. Cell Rep. 2020;30:1271–81.

248. DeRidder L, Sharma A, Liaw K, Sharma R, Hoover J, Kanan S, et al. Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances β-amyloid phagocytosis. Nanoscale. 2021;13:5399–52.

249. Hussain G, Huang J, Rasul A, Anwar H, Imran A, Macbool J, et al. Putative roles of plant-derived tannins in neurodegenerative and neuropsychiatric disorders: an updated review. Molecules. 2019;24:2213.

250. Espin JC, González-Sanías A, Tomás-Barberán FA. The gut microbiota: a key factor in the therapeutic effects of (poly)phenols. Biochem Pharmacol. 2017;139:82–93.

251. Cao P, Chen CM, Liu A, Shan QH, Zhu X, Jia CH, et al. Early-life inflammation promotes depressive symptoms in adolescence via microglial engulfment of dendritic spines. Neuron. 2021;109:2573–89.

252. Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987–91.

253. Ji J, Xue TF, Guo XD, Yang J, Guo RB, Wang J, et al. Antagonizing peroxisome proliferator-activated receptor γ facilitates M1-to-M2 shift of microglia by enhancing autophagy via the LKB1-AMPK signaling pathway. Aging Cell. 2018;17:e12774.

254. Jia XN, Gao ZH, Hu HL. Microglia in depression: current perspectives. Sci China Life Sci. 2021;64:911–25.

255. Hammond TR, Dufton C, Dissing-Olesen L, Giera S, Young A, Wysoker A, et al. Single-cell RNA sequencing of microglia throughout the mouse central nervous system. Immunity. 2019;50:253–71.